Tapi[INVESTIGATOR_222143].: DMVT -505-[ADDRESS_341669] or Independent Ethics Committee.  The information is only to be used by [CONTACT_222184].  You will not disclose an y of the 
information to others without written authorization from Dermavant Sciences , Inc., except to the extent necessary to obtain 
informed consent from those persons to whom the drug may be administered.  
Confidential  Page | 1  
 
 
 
 
 
Clinical Study Protocol  
Study Title:  Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and 
Pharmacokinetics of Tapi[INVESTIGATOR_191751], 1% in Pediatric Subjects with 
Extensive Atopic Dermatitis  
Sponsor:  Dermavant Sciences, Inc.  
[ADDRESS_341670]  
Morrisville, NC, [LOCATION_003]  [ZIP_CODE]  
Compound Name:  [CONTACT_279997][INVESTIGATOR_191752] (DMVT -505) 
Protocol Number:  DMVT -505-2104  
Indication:  Atopic Dermatitis  
Development Phase:  2 
IND Number:  104601  
Current Version:  4.0 
Original Protocol 
Approved/Effective Date  3/25/2021  
Amendment 1 
Approved/ Effective Date:   
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 2  
 
Sponsor Signature [CONTACT_222226]:  Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and 
Pharmacokinetics of Tapi[INVESTIGATOR_191751], 1% in Pediatric Subjects with Extensive 
Atopic Dermatitis  
Protocol Number:  DMVT -505-2104  
  
  
  
This protocol has been approved by a representative of Dermavant Sciences, Inc.  The following signature 
[CONTACT_139142].  
 
 
 
 
  25 Aug 2021  
 Date  
  
 
This electronic signature [CONTACT_280022].  
 
 
 
 
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 4  
Investigator Statement  
 
 
Study Title:  Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and 
Pharmacokinetics of Tapi[INVESTIGATOR_191751], 1% in Pediatric Subjects with Extensive 
Atopic Dermatitis  
  
 
• I confirm agreement to conduct the study in compliance with the protocol.  
• I acknowledge that I am responsible for overall study conduct.  I agree to personally conduct or 
supervise the described study.  
• I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the 
study are informed about their obligations and comply with the study p rotocol.  Mechanisms are 
in place to ensure that site staff receives the appropriate information throughout the study.  
 
 
 
 
 
Princip al Investigator  Name   [CONTACT_280023][INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 6 5.1.4  Preparation  ................................ ................................ ................................ ................................ .... 34 
5.1.5  Administration of Study Drug  ................................ ................................ ................................ ...... 34 
  ................................ ................................ ..................  36 
5.2 Randomization/Treatment Assignment  ................................ ................................ ........................  36 
5.3 Blinding  ................................ ................................ ................................ ................................ ........  36 
5.4 Compliance with Study Drug Administration  ................................ ................................ ..............  36 
5.5 Treatment after the End of the Study  ................................ ................................ ............................  37 
5.6 Prior and Concomitant Therapy  ................................ ................................ ................................ .... 37 
5.6.1  Permitted Medications and Nondrug Therapi[INVESTIGATOR_014]  ................................ ................................ ...........  37 
5.6.2  Prohibited Medications and Nondrug Therapi[INVESTIGATOR_014]  ................................ ................................ ..........  37 
6 Study Assessments and Procedures  ................................ ................................ ..............................  38 
6.1 Demography, Medical History, and Baseline Characteristics  ................................ ......................  38 
6.1.1  Demographics  ................................ ................................ ................................ ...............................  38 
6.1.2  Medical History  ................................ ................................ ................................ ............................  38 
6.2 Efficacy Assessments  ................................ ................................ ................................ ...................  38 
6.2.1  Assessments Completed by [CONTACT_10670]  ................................ ................................ ......................  38 
[IP_ADDRESS]  Validated Investigator Global Assessment  ................................ ................................ ...................  38 
[IP_ADDRESS]  Body Surface Area Affected  ................................ ................................ ................................ .........  [ADDRESS_341671]  ................................ ................................ .............................  39 
[IP_ADDRESS]  Peak Pruritus Numeric Rating Scale ................................ ................................ .............................  39 
6.3 Safety Assessments  ................................ ................................ ................................ .......................  40 
6.3.1  Adve rse Events  ................................ ................................ ................................ .............................  40 
6.3.2  Brief Physical Examination  ................................ ................................ ................................ ..........  40 
6.3.3  Vital Signs  ................................ ................................ ................................ ................................ .... 40 
6.3.4  Clinical Safety Laboratory Assessments  ................................ ................................ ......................  40 
6.3.5  Investigator Assessed Local Tolerability Scale  ................................ ................................ ............  41 
6.4 Treatment of Study Drug Overdose  ................................ ................................ ..............................  42 
6.5 Pharmacokinetics  ................................ ................................ ................................ ..........................  42 
6.6 Virtual Assessments  ................................ ................................ ................................ ......................  42 
7 Timing of Procedures and Assessments  ................................ ................................ .......................  44 
7.1 Visit 1; Screening Period (Day -30 to Day -1) ................................ ................................ .............  44 
7.2 Visit 2; Baseline (Day  1) ................................ ................................ ................................ ..............  45 
7.3 Visit 3; Week  1 (Day  8 ±2 Days)  ................................ ................................ ................................ . 45 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341672] at Day 15 ±2 Days  ................................ ................................ ................................  46 
7.5 Visit 4; Day 28 ±2 Days  ................................ ................................ ................................ ...............  46 
7.6 Visit 5; Follow -Up (Day 35 ±3 Days)  ................................ ................................ ..........................  [ADDRESS_341673]  ................................ ................................ ...............................  51 
8.2 Classification of Adverse Events  ................................ ................................ ................................ .. 52 
8.2.1  Assigning Severity Rating for Adverse Events  ................................ ................................ ............  52 
[IP_ADDRESS]  Criteria for Determining Adverse Event Severity  ................................ ................................ ........  52 
[IP_ADDRESS]  Toxicity Management Criteria  ................................ ................................ ................................ ...... 52 
[IP_ADDRESS].1  Grade 1  or Grade 2  Adverse Event  ................................ ................................ ...............................  52 
[IP_ADDRESS].2  Grade 3  Adverse Event  ................................ ................................ ................................ .................  53 
[IP_ADDRESS].3  Grade 4  Adverse Event  ................................ ................................ ................................ .................  53 
[IP_ADDRESS].4  Folliculitis  ................................ ................................ ................................ ................................ ..... 53 
[IP_ADDRESS].5  Other Management Criteria  ................................ ................................ ................................ ..........  53 
8.2.2  Assigning Causal Relationship to Study Drug  ................................ ................................ .............  53 
8.3 Time Period and Frequency for Event Assessment and Follow -Up ................................ .............  54 
8.3.1  Adverse Event Reporting  ................................ ................................ ................................ ..............  54 
8.3.2  Follow -Up of Adverse Events  ................................ ................................ ................................ ...... 54 
8.4 Reporting Procedures  ................................ ................................ ................................ ....................  54 
8.4.1  Serious Adverse Event Reporting  ................................ ................................ ................................ . 54 
8.4.2  Regulatory Reporting Requirements for Serious Adverse Events  ................................ ...............  55 
8.5 Pregnancy Management and Reporting  ................................ ................................ ........................  55 
9 Data Management  ................................ ................................ ................................ .........................  57 
10 Statistical Considerations and Data Analyses  ................................ ................................ ...............  58 
10.1  General Considerations  ................................ ................................ ................................ .................  58 
10.2  Determination of Sample Size  ................................ ................................ ................................ ...... 58 
10.3  Analysis Populations  ................................ ................................ ................................ ....................  58 
10.3.1  Safety  ................................ ................................ ................................ ................................ ............  58 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341674]/Independent Ethics Committee Approval  ................................ ........  60 
11.1.3  Informed Consent/Assent  ................................ ................................ ................................ .............  60 
11.1.4  Confidentiality  ................................ ................................ ................................ ..............................  61 
11.1.5  Study Files and Retention of Records  ................................ ................................ ..........................  61 
11.1.6  Case Report Forms  ................................ ................................ ................................ .......................  62 
11.1.7  Drug Accountability  ................................ ................................ ................................ .....................  62 
11.1.8  Inspections  ................................ ................................ ................................ ................................ .... 63 
11.1.9  Protocol Compliance  ................................ ................................ ................................ ....................  63 
11.2  Sponsor Responsibilities  ................................ ................................ ................................ ...............  63 
11.2.1  Protocol Modifications  ................................ ................................ ................................ .................  63 
11.2.2 Study Report and Publications ................................ ................................ ................................ ...... 63 
11.2.3  Posting of Information on Publicly Available Clinical Trial Registers  ................................ ........  63 
11.3  Joint Investigator/Sponsor Responsibilities  ................................ ................................ ..................  63 
11.3.1  Access to Information for Monitoring  ................................ ................................ ..........................  63 
11.3.2  Access to Information for Auditin g or Inspections  ................................ ................................ ...... 64 
11.3.3  Study Discontinuation  ................................ ................................ ................................ ..................  64 
12 References  ................................ ................................ ................................ ................................ ..... 65 
13 Appendices  ................................ ................................ ................................ ................................ ... 66 
  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 9 Table of Tables  
Table 1:  Schedule of Assessments  ................................ ................................ ................................ ..............  18 
Table  2: Tapi[INVESTIGATOR_191751]  ................................ ................................ ................................ ...........................  34 
Table  3: Validated Investigator Global Assessment Scale for Atopic Dermatitis  ................................ ...... 39 
Table 4:  Laboratory Tests  ................................ ................................ ................................ ...........................  41 
Table  5: Criteria for Determining the Grade/Severity of Adverse Event Terms Not Specified by [CONTACT_222185]  ................................ ................................ ................................  52 
Table 6.  Calculation of Percent Body Surface Area Affected  ................................ ................................ .... 69 
Table 7.  Calculation of Eczema Area and Severity Index score for Ages 8 Years and Above  ..................  71 
Table 8.  Calculation of Eczema Area and Severity Index Score for Ages < 8 Years  ................................  72 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341675] quantifiable 
concentration  
BID twice daily  
BMI  body mass index  
BSA  body surface area  
%BSA  percent of total body surface area  
BUN  blood urea nitrogen  
CBP  child -bearing potential  
CFR  Code of Federal Regulations  
Cmax maximum plasma concentration  
CRF  case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
CV cardiovascular  
Dermavant  Dermavant Sciences , Inc.  
EASI  Eczema Area and Severity Index  
ET early termination  
FU follow -up 
[COMPANY_004]  GlaxoSmithKline  
HBsAg  hepatitis B surface antigen  
ICF informed consent form  
IEC Independent Ethics Committee  
IND Investigational New Drug Application  
IL Interleukin  
IRB Institutional Review Board  
LTS Local Tolerability Scale  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin  concentration  
MCV   mean corpuscular volume  
NA not applicable  
Nrf2  nuclear factor erythroid 2 -related factor 2  
P/C phone contact  
[CONTACT_279997][INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 11 Term  Full Description  
PGA  Physician’s Global Assessment  
PK Pharmacokinetic (s) 
PP-NRS  Peak Pruritus -Numeric Rating Scale  
QD once daily  
RBC  red blood cell(s)  
SAE  serious adverse event  
SD standard deviation  
TAMA  therapeutic AhR -modulating agent  
TEAEs  treatment emergent adverse events  
tlast time of last quantifiable concentration  
tmax time to maximum plasma concentration  
ULN  upper limit of normal  
V visit 
vIGA -AD™ validated Investigator Global Assessment for Atopic Dermatitis™  
WBC  white blood cell(s)  
  
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 12 Synopsis        
Name [CONTACT_790]/Company:  
Dermavant Sciences , Inc.  
Name [CONTACT_791]:  
DMVT -505 (tapi[INVESTIGATOR_191753], 1%)  
Name [CONTACT_3261]:   
Tapi[INVESTIGATOR_222145]:  DMVT -505-2104  Phase:  2 Country:  [LOCATION_002]  and Canada  
Title of Study:  
Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapi[INVESTIGATOR_191751], 1% in Pediatric 
Subjects with Extensive Atopic Dermatitis  
Study Center(s):  
Approximately  12 sites  in the U nited States and Canada  
Objectives:  
Primary:  
• To evaluate the safety and tolerability of tapi[INVESTIGATOR_191753], 1% once daily in pediatric subjects ages 2 to 17 years old with 
extensive atopic dermatitis (AD)  
• To evaluate the pharmacokinetics (PK) of tapi[INVESTIGATOR_191753], 1% once daily in pediatric subjects ages 2 to 17 years old with 
extensive AD  
Second ary: 
• To assess the efficacy of tapi[INVESTIGATOR_191753], 1% once daily in pediatric subjects ages 2 to 17 years old with extensive AD  
Methodology:  
This is a Phase 2a, multicenter, open -label, safety, tolerability and PK study  in subjects ages [ADDRESS_341676] of three phases:  Screening (up to 30 days), Treatment (2 7 days), and Follow -up (approximately 7 days).  
At Day 1 (Baseline), eligible subjects and/or their caregiver(s) will be instructed on how to apply tapi[INVESTIGATOR_191753], 1% whil e under 
the supervision of site personnel in the clinic  and have collection of PK samples to assess systemic absorption .  During the 
treatment period, subjects and/or their caregiver(s) will apply tapi[INVESTIGATOR_191753], 1% to affected areas once a day for 28 day s, 
including newly appearing lesions and lesions/areas that improve during the study.  Subjects or caregivers will apply suffici ent 
study drug to cover completely each lesion with a thin layer of study drug and will record the time of study drug applicatio n and 
daily itch score (Peak Pruritus -Numeric Rating Scale [PP -NRS]) in a daily diary provided by [CONTACT_3452].  (Note that subjects are 
allowed, but not required, to treat scalp lesions with study drug; however, efficacy analyses will not include assess ment of AD in 
this area.)  Subjects will return to the clinic on Days 8 and 28 for study assessments.  On clinic visit days, subjects and/o r their 
caregiver(s) will apply study drug under the supervision of site personnel.  Additionally, subjects will be c ontacted by [CONTACT_279998] 15 to assess adverse events ( AEs) and concomitant medications, to review study drug administration instructions, and to 
confirm subject’s continued participation in this study.  
At the end of the [ADDRESS_341677] the option to enroll 
in a separate open label long -term safety study for an additional 48 weeks of treatment.  Subjects who choose not to participate in 
the open -label long -term safety study or who  fail to qualify for participation in the open -label long -term safety study will complete 
a Follow -up visit (Day 35) approximately [ADDRESS_341678] been enrolled (25% of the study), the PK data will be evaluated with the potential to eliminate the [ADDRESS_341679] -dose 
sampling time point on Day 1.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 13 Number of Subjects:  
Approximately 36 subjects a ges 2 to 17 years old will be enrolled in the study with approximately 12 subjects, and a minimum of 
10 subjects, enrolled into each of the three following age cohorts: 2 -6 years old, 7 -11 years old, 12 -17 years old.    
Diagnosis and Main Criteria for Inclusion:  
Inclusion Criteria:  
Each subject must meet all the following criteria to be eligible to participate in the study:  
1. Male and female subjects ages 2 to 17 years old with clinical diagnosis of AD by [CONTACT_222188].  
2. Subjects with AD cov ering ≥25% of the body surface area (BSA) for subjects ages 12 -17 years old, or ≥35% of the BSA 
for subjects ages 2 -11 years old.  Scalp should be excluded from the BSA calculation to determine eligibility during 
Screening and at Baseline, and for all effi cacy assessments.   
3. A Validated Investigator Global Assessment in Atopic Dermatitis (vIGA -AD™) score of 3 or greater at Screening and 
Baseline (pre -dosing ). 
4. AD present for at least 6 months for subjects ages 6 -17 years old or 3 months for subjects ages 2 to 5years old, confirmed 
by [CONTACT_222196]/or according to the subject and/or caregiver(s).  
5. Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use one 
of the following acceptab le birth control methods while on study and for [ADDRESS_341680] exposure to study drug.   
• Acceptable contraception methods include intrauterine device, hormonal contraceptives, barrier method (e.g., 
condom or diaphragm), or surgical sterilization of  male partner (vasectomy)  
• Subjects who claim abstinence as their method of contraception are allowed provided they agree to use a barrier 
method (e.g., condom or diaphragm) should they become sexually active from Screening to [ADDRESS_341681] dose o f study drug  
Non-child -bearing potential is defined as:  
• Premenarchal  
• Pre-menopausal females with a documented bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or 
hysteroscopic sterilization  
6. Female subjects of childbearing potential must ha ve a negative serum pregnancy test at Screening and a negative urine 
pregnancy test at Baseline (Day 1).  
7. Subject, subject’s parent(s), or legal representative must be capable of giving written informed consent, which includes 
compliance with the requiremen ts and restrictions listed in the consent/assent form; written informed consent must be 
obtained prior to any study related procedures  
Exclusion Criteria:  
A subject who meets any of the following criteria will be excluded and considered ineligible for participation in the study:  
1. Concurrent conditions:  
a. Immunocompromised (e .g., lymphoma, acquired immunodeficiency syndrome) or medical history of positive 
huma n immunodeficiency virus antibody at Screening.  
b. Chronic or acute systemic infection requiring treatment with, antiparasitics or antiprotozoals, within 4 weeks 
prior to the Baseline visit.  
c. Chronic or acute systemic bacterial infection requiring treatment with systemic antibiotics within one week prior 
to the Baseline visit.  
d. Chronic or acute superficial fungal infection requiring treatment with systemic antifungals within one week prior 
to the Baseline visit.  
e. Acute active bacterial, fungal, or viral (herpe s simplex, herpes zoster, chicken pox) skin infection within one 
week prior to the Baseline visit; the condition should be completely resolved one week prior to Baseline Visit.  
f. Significant dermatologic or inflammatory condition other than AD that, in the I nvestigator’s opi[INVESTIGATOR_1649], would 
make it difficult to interpret data or assessments during the study.   For example, subjects with an active skin 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 14 condition such as Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo, psoriasis, severe 
acne, connective tissue disorder, or Netherton's syndrome, or any other concurrent active disease.  
g. Concurrent skin lesions in the treatment area or pruritus due to conditions other than AD that, in the opi[INVESTIGATOR_15960], would either interfere with  study evaluations or affect the safety of the subject.  
2. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.0 x the upper limit of normal (ULN).  
3. Screening total bilirubin > 1.5x ULN; total bilirubin > 1.5x ULN is acceptable i f bilirubin is fractionated and direct 
bilirubin < 35%.  
4. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert’s 
syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBs Ag), or positive hepatitis C antibody 
test result, or presence of anti -hepatitis B core antigen (anti -HBc). Subjects having a negative HBsAg and a positive anti -
HBc may enroll if they have a positive anti -hepatitis B surface antigen demonstrating natural i mmunity. Subjects with a 
history of hepatitis C virus  infection who were medically cured and have an undetectable viral load are eligible to enroll. 
Subjects with a history of stable non -alcoholic fatty liver disease without evidence of active inflammation  (elevated 
ALT/AST ≥ 2.[ADDRESS_341682]) or cirrhosis are eligible to enroll.  
5. Current or a history of cancer within 5 years except for adequately treated skin basal cell carcinoma, cutaneous squamous 
cell carcinoma or carcinoma in situ of the cervix (surgical excis ion or electrodessication and curettage).  
6. Subjects who would not be considered suitable for topi[INVESTIGATOR_8588] (e.g., those with extensive disease involvement over a 
large BSA who would be candidates for systemic therapy).  
7. Use of any prohibited medication or procedure within the indicated period before the Baseline visit.  
NOTE :  Prohibited concomitant medications, therapy, etc. during the defined period are as listed in the bullets below.  If 
a subject requires any of these medications throughout the study period, he/she may be excluded from or discontinued 
from the study, at t he discretion of the Investigator and Medical Monitor.  
a. From 4 months prior to Baseline until the completion of the Follow -up visit or study discontinuation:  
• DUPI[INVESTIGATOR_24786] t® (dupi [INVESTIGATOR_12458] ) injection.  
• Any monoclonal antibody product that becomes approved for AD du ring the course of the trial.  
b. From 28 days prior to Baseline until the completion of the Follow -up visit or discontinuation:  
• Oral, injectable, and suppository preparations of corticosteroids. Eye drops and nasal preparations are 
allowed.  Inhaled preparat ions are allowed when used for a stable condition and stable dose for ≥ 28 
days before Screening and are continued at the same dose throughout the study.  
• Oral preparations and injections of immunosuppressants (cyclosporine, methotrexate, azathioprine, 
tacrolimus, Janus kinase inhibitors, etc.).  
• Excessive sun exposure, tanning booth, other ultraviolet light source and phototherapy including 
psoralen and ultraviolet A therapy or is unwilling to minimize natural and artificial sunlight exposure.  
• Treatment wi th antivirals with the exception of short -term treatment for acute upper respi[INVESTIGATOR_190318] (i.e., influenza) or viral suppressive therapy for a history of recurrent herpes labialis or 
genital herpes.  
c. From 14 days prior to Baseline until the comp letion of the Follow -up visit or discontinuation:  
• EUCRISA® (crisaborole) and any other PDE4 inhibitor.  
• Tacrolimus ointment and pi[INVESTIGATOR_71861].  
• Topi[INVESTIGATOR_222151] (e.g., fluocinonide, triamcinolone 
acetonide) or super -high potency (e .g., clobetasol propi[INVESTIGATOR_16847]).   Eye drops and nasal preparations are 
allowed.  
• Coal tar products (on the body).  If subject chooses to treat scalp with study drug, then coal tar products 
are prohibited for use on the scalp.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 15 • Over the counter or herbal medicines for AD (topi[INVESTIGATOR_222153]). If subjects are using 
emollients, they may continue to use the same emollient on nonlesional skin during the study.  
Emollients containing salicylic acid are prohibited during the study.  
d. From 7 days prior to Baseline until the completion of the Follow -up visit or discontinuation:  
• Topi[INVESTIGATOR_222167] (e.g., desonide, hydrocortisone).  
• Oral, injectable, or intravenous antibiotics  or antifungal me dications.  
• Topi[INVESTIGATOR_222168] , topi[INVESTIGATOR_222169], or topi[INVESTIGATOR_222156] . 
NOTE:  Oral doxepin is allowed for treatment of depression if subject has been on a stable dose (4 
weeks) at Screening . 
• Topi[INVESTIGATOR_57961], except for the treatment of follicular events  
• Antihistamines/antiallergics (oral, topi[INVESTIGATOR_222157]):  diphenhydramine, chlorpheniramine 
maleate, hydroxyzine.  
NOTE:  The following antihistamines are allowed from Screening throughout the treatment period: 
loratadine, fexofenad ine hydrochloride, cetirizine hydrochloride.  Subjects are  allowed to switch from 
non-allowed antihistamines during Screening  but must be on a stable dose for [ADDRESS_341683] dosing day 
in the current study:  [ADDRESS_341684] (whichever is longer).  
8. A history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investig ator’s opi[INVESTIGATOR_1649], 
may interfere with the subject’s participation in the study, interpretation of results, or ability to understand and give 
informed consent.  
9. Pregnant females as determined by [CONTACT_222190] (Screening) or urine (Baseline) human chorionic go nadotropin test.  
10. Lactating females.  
11. History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the 
opi[INVESTIGATOR_24245], contraindicates their participation.  
12. Previous k nown participation in a clinical study with tapi[INVESTIGATOR_191752] (previously known as [COMPANY_004]2894512 and WBI -1001 ). 
Investigational Product, Dosage and Mode of Administration:  
Tapi[INVESTIGATOR_191753], 1% is a white to off -white cream containing 1% weight /weight  (10 mg/gram) tapi[INVESTIGATOR_191752], supplied in [ADDRESS_341685] and/or caregiver(s) once daily via topi[INVESTIGATOR_55594] a thin layer to aff ected 
areas.  
Reference Therapy, Dosage and Mode of Administration:  
n/a 
Duration of Treatment:  
Study duration for subjects who complete this Phase 2a study and do not enroll in the open -label long -term safety study is 
approximately 9 weeks in total (including approximately 30 days for Screening, 2 7 days of treatment, and a 1 week follow -up 
period).  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 16 Criteria for Evaluation:  
Pharmacokinetic 
Assessments:  • Plasma concentrations of tapi[INVESTIGATOR_222159]:  • AEs 
• Vital signs  
• Physical examinations  
• Clinical laboratory tests  
• Investigator -assessed Local Tolerability Scale (LTS)  
Efficacy Assessments:  • vIGA -AD™  
• Eczema Area Severity Index (EASI)  
• Percentage of total body surface area (%BSA) affected  
• PP-NRS  for completion by [CONTACT_222191] ≥ 12 years and for completion by [CONTACT_279999] < 12 years  
Study Endpoints:  
Primary:  
• Incidence, frequency, and duration of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)  
• Change from Baseline in laboratory values  
• Change from baseline in vital signs  
• Mean Investigator -assessed LTS scores by [CONTACT_765] (overall and sensitive areas)  
• Tapi[INVESTIGATOR_279965] 1, if data permit, including:  
o area under the plasma concentration versus time curve from time zero to the last quantifiable 
concentration (AUC 0-last) 
o maximum plasma concent ration (C max) 
o time to maximum plasma concentration (t max) 
o time of last quantifiable concentration (t last) 
• Tapi[INVESTIGATOR_279966] 28  
Secondary:  
• Change in vIGA -ADTM score from Baseline at each study visit  
• Proportion of subjects who have a vIGA -ADTM score of clear or almost clear (0 or 1) at each study visit  
• Proportion of subjects with ≥50% improvement in EASI score from Baseline at each study visit   
• Proportion of subjects with ≥75% improvement in EASI score from Baseline at each study visit  
• Proportion of subjects with ≥90% improvement in EASI score from Baseline at each study visit  
• Mean change and percent change in EASI score from Baseline at each study visit  
• Mean change and percent change in %BSA affected from Baseline at each study visit  
• Mean change and percent change in BSA  x vIGA -AD™ values from Baseline at each study visit  
• Proportion of subjects with a Baseline PP -NRS score ≥ 4 who achieve ≥ 4-point reduction in the PP NRS from Baseline 
at each study visit  
• Proportion of subjects ≥ 12 yea rs old with a Baseline PP -NRS score ≥4 who achieve a ≥4 -point reduction in PP -NRS 
score from Baseline at each study visit  
• Proportion of subjects 2 to < 12 years old with a Baseline PP -NRS score ≥4 who achieve a ≥4 -point reduction in PP -NRS 
score from Basel ine at each study visit  
• Mean change in PP -NRS score from Baseline to Day 28  at each study visit  by [CONTACT_280000]:   
Safety Analyses:  
• Analyses of the safety endpoints will be based upon the Safety population, which is defined as all enrolled  subjects who 
receive at least 1 application of study drug.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 17 • AEs will be summarized as incidence rates of any AEs, TEAEs, AE s of special interest, treatment -related TEAE s, 
TEAE s leading to study drug discontinuation,  TEAEs leading to study discontin uation, and SAEs.  
• Changes in laboratory parameters and vital signs will be summarized using shift tables and descriptively for quantitative 
measures by [CONTACT_765].   
• LTS scores will be summarized  by [CONTACT_765] . 
Pharmacokinetics:  
• Plasma concentration data will be listed and summarized by [CONTACT_15449].  PK parameters will be presented in tabular 
and/or graphical format and summarized descriptively if data permit  
Efficacy Analyses:  
• Analyses of efficacy endpoints will be based upon the Safety population.  Proportions  will be summarized using 
frequency counts and percentages, and mean changes and percent changes will be summarized using descriptive statistics 
(mean, median, standard deviation, minimum and maximum).  
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 18 Schedule of Assessments  
Table 1: Schedule of Assessments   
Procedures and Assessment  Screening  Treatment Phase  FUa ETb 
V1 V2 V3 P/C V4 V5 NA 
Day -30 
to  
Day -1 Baseline ,  
Day 1  Day 8  
(±1 day)  Day 15  
(±2 days)  Day 28  
(±2 days)  Day 35  
(±3 days)  NA 
Informed consent  X       
Inclusion and exclusion criteria  X X      
Demography  X       
Fitzpatrick skin type  X       
Brief physical examc X X X  X X X 
Medical historyd X Xe      
Pregnancy test (females of child -bearing potential)f X Xg   X  X 
Blood sample for clinical laboratory assessmentsh X    X Xi X 
Urinalysis  X    X Xi X 
Vital signsj X X X  X X X 
Study drug Dispensation / Collectionk  D C/D  C  C 
Review instructions for study drug  applicationl  X X X    
Dispense/collect subject diary of study drug application    D C/D  C  C 
Tapi[INVESTIGATOR_279967] -clinic under site supervisionm  X X     
PK samplesn X X   X   
AE/SAE review  X X X X X X X 
Concomitant medication review  X X X X X X X 
vIGA -ADTM scoreo X X X  X X X 
%BSA affectedp X X X  X X X 
EASIp  X X  X X X 
LTS assessment by [CONTACT_280001]  X X  X   
PP-NRS (assessed pre -dose at visit, as applicable)r  X X  X   
Enrollment (optional) in open -label long -term safety study      X   
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341686] who terminates early . 
b. Subjects who withdraw from the study before Day 28 (Visit 4) will complete an Early Termination Visit.  
c. Physical examination will include height and weight, (BMI will be  calculated in the CRF); a brief physical examination will be performed at other visits.  
d. Medical history will include month and year of AD diagnosis.   As part of the subject’s medical history, all systemic (oral and injectable) medications used by [CONTACT_941] s ubject for 
treatment of AD prior to [ADDRESS_341687] the weight of all tubes dispensed at each visit in the  drug accountability logs.  Site personnel will weigh the 
returned tubes (used and unused) and record the weight in the drug accountability logs.  If a tube has been lost, discarded, or forgotten by [CONTACT_423], then the site personnel will make 
a notation of this on the drug accoun tability logs.  
l. Subjects and/or caregivers will be instructed to apply study drug once daily at the approximate same time each day, based on subject and/or caregiver(s) preference.  
m. At all clinic visits, study drug will be applied after all safety and efficacy assessments have been conducted.    
n. The blood sample collected at Screening will serve as the pre -dose plasma concentration.  PK sampling will occur on Day [ADDRESS_341688] -dose.  A single PK sample will 
be collected on Day 28.  
o. The  vIGA -ADTM assessment should be performed before the %BSA and EASI assessments.  
p. The subject's scalp should be excluded from the %BSA and EASI calculation.  
q. The LTS assessment should be conducted pre -dose. 
r. PP -NRS daily itch diaries will be dispensed  at Day 1 (Baseline) and Day 8 and collected on Day 28 . 
%BSA = percent of total body surface area; AD = atopic dermatitis; AE = adverse event (s); BMI = body mass index; BP = blood pressure; C = study drug collection; CRF = case 
report form; D = study drug  dispensation; ET = early termination; EASI = Eczema Area and Severity Index; Hep = hepatitis; HIV = human immunodeficiency vi rus; HR = heart rate; 
LTS = Local Tolerability Scale; NA = not applicable; P/C = phone call; PK = pharmacokinetic; SAE = serious a dverse event; vIGA -ADTM = Validated Investigator Global 
Assessment in Atopic Dermatitis  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 20 1 Introduction   
1.1 Background Information and Study Rationale   
1.1.1 Background Information   
Atopic dermatitis (AD) (also called atopic eczema) is an intensely pruritic, chronic, re lapsing, inflammatory 
skin disease [ Bieber , 2008].  The characteristic signs and symptoms of AD include sensations of pruritis and 
burning, xerosis, erythema tous papules and plaques, exudation, crusting, and lichenification.  Quality of life is 
affected through sleep deprivation due to the intense and constant itching, as well as the stigma associated 
with having a visible skin disease [ Carroll , 2005; Lewis -Jones , 2006].  Up to 30% of children may be affected  
by [CONTACT_280002], and 2% to 10% of adults have AD [ Bieber , 2008].  Currently there is no curative 
therapy.  Stabilizing the disease and reducing the number and severity of flares are the primary goals of 
treatment.  Topi[INVESTIGATOR_279968] a key factor in disease management, as is 
symptomatic relief of itching.  Although multiple topi[INVESTIGATOR_191762], there still remains a 
need for a topi[INVESTIGATOR_279969] a high level of efficacy with an acceptab le safety profile that 
permits application to a large body surface area (BSA) without restrictions on duration of treatment.  
Tapi[INVESTIGATOR_191752] (DMVT -505), formerly known as [COMPANY_004]2894512 and WBI -1001, is a fully synthetic naturally 
derived stilbene that is being deve loped by [CONTACT_280003] , Inc.  (Dermavant) as a novel 
anti-inflammatory agent for the topi[INVESTIGATOR_279970].  The compound (number WBI -
1001) was initially developed by [CONTACT_191829].  (Welichem; Burnaby, British Columbia, Canada) 
and then was acquired by [CONTACT_35316] ([COMPANY_004]) on [ADDRESS_341689] 2018  for continued development.   
Development of tapi[INVESTIGATOR_279971] n is being jointly pursued with Japan Tobacco Inc. (JT), with a Phase 
3 program in PSO and AD scheduled to commence in late 2021.  In China, the compound was independently 
developed by [CONTACT_280004]. (BWTP) (Shenzhen C elestial) under 
the name [CONTACT_280024] (active ingredient corresponds to tapi[INVESTIGATOR_191752]).  BWTP was granted authorization to market 
benvitimod cream (a different formulation and excipi[INVESTIGATOR_279972]) as Symbiox® 
in China in July 2019.  
Tapi[INVESTIGATOR_191753], 1% is a white to off -white, oil -in-water emulsion intended for topi[INVESTIGATOR_279973], which has a novel mechanism of action.  Tapi[INVESTIGATOR_279974] a nonsteroidal, small molecule 
therapeutic aryl hydrocarbon receptor (Ah R) modulating agent (TAMA)  which exerts its therapeutic effects 
via agonism of AhR, a cytosolic ligand dependent transcription factor.  Upon ligand binding, AhR 
translocates to the nucleus and dimerizes with AhR nuclear translocator (ARNT) forming an AhR A RNT 
heterodimer  [Smith , 2017]. The AhR -ARNT heterodimer modulates gene transcription through direct and 
indirect interaction with DNA. By [CONTACT_280005] A hR signaling pathway, tapi[INVESTIGATOR_279975] -inflammatory cytokines, including interleukin (IL)-4, IL -5, IL -6, IL -13, 
IL-17A and F , and eotaxin , and upregulate the expression of several skin barrier proteins, incl uding filaggrin, 
hornerin, and involucrin.   In addition, A hR also activates the antioxidative transcription factor nuclear factor -
erythroid 2 -related factor -2 (Nrf2), upregulating the expression of antioxidative enzymes [Smith , 2017; Furue  
2019 ].  By [CONTACT_280006], t api[INVESTIGATOR_279976] a biological profile that differs from that of currently available 
products, offering patients a truly novel therapeutic treatment option .   
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 21 Two Phase  2b, 12-week, randomized, double -blind, vehicle -controlled, 6 -arm, parallel group, dose -finding 
studies with topi[INVESTIGATOR_191773]; 1  study each in subjects with AD or 
psoriasis.  These 2  studies evaluated the safety and effica cy of tapi[INVESTIGATOR_191753] (Formulation F) at 
2 concentrations (0.5% or 1% weight/weight [ w/w]) and 2  application frequencies (once daily [QD] or twice 
daily [BID]) in [ADDRESS_341690] compared with vehicle, with the 1% w/w 
concentration treatment groups demonstrating a higher proportion of subjects with treatment success 
compared with the 0.5% w/w concentration groups (applied QD and BID in the AD study).  In both 
indications, the tapi[INVESTIGATOR_191752]  1% dosing groups showed a faster onset of action than the 0.5% dosing groups, and 
QD application had similar efficacy to BID application.  In both Phase  2b studies, tapi[INVESTIGATOR_279977].  Treatment -emergent adverse events (TEAEs) were reported with a higher frequency 
in the tapi[INVESTIGATOR_279978].  The most frequent TEAEs (≥  5% in any arm or in total) 
were nasopharyngitis, folliculitis, dermatitis contact, atopic dermatitis, upper respi[INVESTIGATOR_1092], 
headache, vomiting, acne, application site dermatitis, miliaria, dermatitis allergic, and impetigo.  The majority 
of TEAEs were mild or moderate in severity.  In each study, the tapi[INVESTIGATOR_191752] 1% QD  treatment group had a 
lower frequency of TEAEs than the tapi[INVESTIGATOR_191752] 1% BID treatment group.  
Tapi[INVESTIGATOR_279979]  3, 12 -week, randomized, double -blind, vehicle -controlled 
trials in adult subjects with plaque psoriasis.  These s tudies evaluated the safety and efficacy of tapi[INVESTIGATOR_222150], 1% once a day versus vehicle cream once a day in a combined 1025  subjects randomized 2:[ADDRESS_341691] vehicle on the primary e ndpoint, a 
Physician Global Assessment (PGA) score of 0 (clear) or 1  (almost clear) with a 2 -point improvement at 
Week  12.  In addition, tapi[INVESTIGATOR_279980] a 75% improvement in the Psoriasis Area and 
Severity Index, a PGA score of 0 or 1, change in percent body surface area (%BSA), and proportion of 
subjects achieving a 90% improvement in PASI at Week  12.  TEAEs were reported with a hig her frequency 
in the tapi[INVESTIGATOR_279981].   The most frequent TEAEs (≥  5% in any arm or in total) were 
folliculitis, nasopharyngitis, and contact [CONTACT_8748].  The majority of TEAEs were mild or moderate in 
severity.   In addition, a 40 -week open label extension study was conducted which confirmed the safety profile 
observed in 12 -week studies with no new safety signals emerging . 
1.1.2 Study Rationale   
This Phase 2a ma ximal use study is being conducted as part of a clinical development program to evaluate the 
safety and systemic exposure of tapi[INVESTIGATOR_191753], 1% for the topi[INVESTIGATOR_279982] [ADDRESS_341692] [ Bashaw , 2014].  The results of this study are intended to 
support product registration in the [LOCATION_002]  and Canada.  
1.2 Rationale for Study Design  and Dose   
The dose of tapi[INVESTIGATOR_279983] 1% cream administered QD, the same as that studied in the Phase 
3 pi[INVESTIGATOR_279984] .  This is also the dose that 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 22 was selected for the  Phase 3 pi[INVESTIGATOR_279985] 203121 
[Peppers , 2019].  In study  203121 , applications of tapi[INVESTIGATOR_279986] 0.5% and 1% applied 
once or QD were evaluated.  The groups treated with a 1% concentration showed higher efficacy and resulted 
in a quicker onset of effect than did the groups treated with a 0.5% concentration.  Efficacy responses began 
as early as Week 2 and continued through Week 12.  The proportion of subjects with ≥ 75% improvement in 
Eczema Area Severity  Index (EASI) was also higher for the 1% BID (60%) and 1% QD (51%) compared to 
vehicle (25 -26%). Overall, both concentrations demonstrated an acceptable safety profile when applied once 
or BID with the 1% QD arm having a lower number of reported TEAEs comp ared to the 1% BID arm (54% 
vs 70%, respectively).  QD application was selected as efficacy was similar between 1% BID and 1% QD 
regimens and provided a better safety profile.  In addition, QD application may improve treatment adherence 
compared with more frequent dosing administrations.  
Extrapolation of tapi[INVESTIGATOR_279987], efficacy, and dosing regimen from adults to adolescents, and to children is 
appropriate on the grounds of similarity of skin development, pharmacokinetics ( PK), formulation 
composition, an d clinical endpoints.  The tapi[INVESTIGATOR_279988].  Furthermore, the skin of infants would be expected to have similar 
barrier function to adults.  Infants born at [ADDRESS_341693] a fully 
functional stratum corneum comparable with that of adults [Kalia , 1998 ].  Another study demonstrated that 
the way the stratum corneum stores and transports water becomes adult -like after the first year of life 
[Nikolovski , 2008 ].  In [COMPANY_004] study 203121, the safety, efficacy, and plasma concentrations of tapi[INVESTIGATOR_279989].  Therefore, there is no evidence to suggest that s afety, efficacy, or 
dosing regimen in the pediatric population down to age [ADDRESS_341694] ives.  This study includes an open label 
treatment phase in which subjects will receive tapi[INVESTIGATOR_191753], 1% QD for [ADDRESS_341695] refer to the 
current version of the tapi[INVESTIGATOR_222161]’s Brochure for detailed information regarding warnings , 
precautions, contraindications, adverse events ( AEs), and other significant data pertaining to the study drug 
being used in this study.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 23   
   
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
   
 
  
 
 
   
 
 
 
 
 
 
 
 
 
     
 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 24    
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Benefit Assessment   
Subjects may experience improvements in their AD during the course of the study and may benefit from the 
additional safety assessments conducted as part of the study (e .g., physical examination, laboratory tests).  
Subjects in the study will also contribute to the process of developi[INVESTIGATOR_007] a novel anti -inflammatory agent for the 
topi[INVESTIGATOR_166474].  Furthermore, subjects participating in this trial will be offered enrollme nt in a long-
term safety study  (DMVT -505-3103) , if eligibility  requirements are met, where they will have continued 
access to tapi[INVESTIGATOR_279990] 48 weeks . 
1.3.3 Overall Benefit Risk   
Taking into account the measures taken to minimize risk to subjects in this study, the potential risks identified 
in association with tapi[INVESTIGATOR_222162].  

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 25 2 Objectives and Endpoi nts  
The objectives and associated endpoints of the study are as follows:  
Objectives  Associated Endpoint  
Primary  
• To evaluate the safety 
and tolera bility  of 
tapi[INVESTIGATOR_191753], 1% QD 
in pediatric subjects ages 
2 to 17 years old with 
extensive AD  • Incidence, frequency and duration of TEAEs and serious adverse events (SAEs)  
• Change from Baseline in laboratory values  
• Change from Baseline in vital signs  
• Mean Investigator -assessed local tolerability scores ( LTS) scores by [CONTACT_765] (overall and 
sensitive areas)  
• To evaluate the PK of 
tapi[INVESTIGATOR_191753], 1% QD 
in pediatric subjects ages 
2 to 17 years old with 
extensive AD  • Tapi[INVESTIGATOR_279965]  1, if data permit, including:  
o area un der the plasma concentration versus time curve from time [ADDRESS_341696] 
quantifiable concentration (AUC 0-last) 
o maximum plasma concentration (C max) 
o time to maximum plasma concentration (t max) 
o time of last quantifiable concentration (t last) 
• Tapi[INVESTIGATOR_279966] 28  
Secondary  Secondary:  
• To assess the efficacy of 
tapi[INVESTIGATOR_191753], 1% QD 
in pediatric subjects ages 
2 to 17 years old with 
extensive AD  • Change in Validated Investigator Global Assessment in Atopic Dermatitis ( vIGA -ADTM) 
score from Baseline  at each study visit  
• Proportion of subjects who have a vIGA -ADTM score of clear or almost clear (0 or 1) at 
each study visit  
• Proportion of subjects with ≥50% improvement in EASI score from Baseline at each study 
visit 
• Proportion of subjects with ≥75% improvement in EASI score from Baseline at each study 
visit 
• Proportion of subjects with ≥90% improvement in EASI score from Baseline at each study 
visit 
• Mean change and percent change in EASI score from Baseline at each stu dy visit  
• Mean change and percent change in %BSA affected from Baseline at each study visit  
• Mean change and percent change in BSA  x vIGA -AD™ values from Baseline at each study 
visit 
• Proportion of subjects with a Baseline PP -NRS score ≥ 4 who achieve ≥ 4-point reduction 
in the PP NRS from Baseline at each study visit  
• Proportion  of subjects  ≥ 12 years old  with a Baseline PP -NRS score ≥4 who achieve a ≥4 -
point reduction in PP -NRS score from Baseline at each study visit  
• Proportion of subjects 2 to < 12 years old  with a Baseline PP -NRS score ≥4 who achieve a 
≥4-point reduction in PP -NRS score from Baseline at each study visit  
• Mean change in PP -NRS score from Baseline to Day 28  by [CONTACT_280007][INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341697] of three phases:  Screening (up to 30 days), Treatment (2 7 days), and Follow -up 
(approximately 7 days).  
At Day 1 (Baseline), eligible subjects and/or their caregiver(s) will be instructed on how to ap ply tapi[INVESTIGATOR_222150], 1% while under the supervision of site personnel in the clinic  and have collection of PK samples to 
assess systemic absorption .  During the treatment period, subjects and/or their caregiver(s) will apply 
tapi[INVESTIGATOR_191753], 1% to affected  areas once a day for 2 7 days, including newly appearing lesions and 
lesions/areas that improve during the study.  Subjects or caregivers will apply sufficient study drug to cover 
completely each lesion with a thin layer of study drug and will record the t ime of study drug application and 
daily itch score (Peak Pruritus -Numeric Rating Scale [PP -NRS]) in a daily diary provided by [CONTACT_3452].  
(Note that subjects are allowed, but not required, to treat scalp lesions with study drug; however, efficacy 
analyses will not include assessment of AD in this area.)  Subjects will return to the clinic on Days 8 and 28 
for study assessments.  On clinic visit days, subjects and/or their caregiver(s) will apply study drug under the 
supervision of site personnel and in structed/reminded on how to apply study drug (except during the final 
treatment/end -of-study visits).  Additionally, subjects will be contact[CONTACT_280008] [ADDRESS_341698]’s continued 
participation in this study, and reminded to complete their daily diary and bring it with them to the next clinic 
visit.  
Study drug will be dispensed and applied to subjects during the clinic visits and will be administered at h ome 
between clinic visits as instructed by [CONTACT_8786].  Subjects and/or caregivers will be advised  to maintain 
the approximate dosing time chosen at the beginning of the study for their full study participation.  
Nonmedicated emollients that do not con tain salicylic acid may be used on nonlesional skin; emollients 
should not be applied to lesional skin during treatment.  The same emollient should be used throughout the 
subject’s participation in the study.  
Study drug application instructions will be rev iewed at all post -baseline  clinic visits and during the planned 
study phone call.  The time of the dose application and assessments will depend on the time of the clinic visit.  
Therefore, the timing of the clinic visit may lead to a change in the subject’ s chosen dosing time for that day.  
On Day [ADDRESS_341699] the option to enroll in a 
separate open -label long -term safety study for an additional 48 weeks. Subjects who choose not to participate 
in the open -label long -term safety study or who fail to qualify for participation in the open -label long -term 
safety study will complete a Follow -up Visit (Day 35) approximately [ADDRESS_341700] not to 
enroll in that study is approximately 9 weeks in total.  S tudy duration for subjects who complete this study 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 27 and are eligible and decide to participate in the open -label long -term safety study is approximately 8 weeks in 
total.  
Efficacy assessments will include v -IGA-ADTM score, %BSA affected, EASI, and PP -NRS.  Safety 
assessments will include AEs, clinical laboratory tests, physical examination, vital signs, and LTS.   
Pharmacokinetics will be assessed at Days [ADDRESS_341701] is enrolled.   Blood sam ples for PK should not be collected from any anatomic site where study 
drug has been applied in order to minimize potential contamination.  
Refer to Section 6 for descriptions of study procedures and assessments and Section 7 and the Schedule of 
Assessments ( Table 1) for timing of procedures and assessments  
3.2 Treatm ent Groups and Duration   
All subjects will receive tapi[INVESTIGATOR_191753], 1% QD for [ADDRESS_341702] complete 4 weeks of assessments.  To be considered a “study 
completer” in terms of treatment period, a subject must complete ≥ 80.0% of the intended doses.  The number 
of intended doses is defined as the study day of the subject’s Day 28  visit minus 1 (e.g., if the subject ’s Day 
28 visit occurs exactly on Day 28 then their number of intended doses is 27).   
To be eligible for the open -label , long -term safety study, subjects must be a “study completer”. Subjects who 
complete the study will have the option to enroll into the Phase [ADDRESS_341703] has completed the 4 weeks of assessments and either 
enrolls in the long -term safety study or does not enroll and completes the Follow -up visit.  
 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341704] udy with approximately 12 subjects, 
and a minimum of 10 subjects, enrolled into each of the three following age cohorts: [ADDRESS_341705] meet all of the following criteria to be eligible to participate in the study:  
1. Male and female subjects ages 2  to 17  years with a clinical diagnosis of AD by [CONTACT_222195] [ Hanifin , 1980] (see Appendix 1). 
2. Subjects with AD covering ≥25% of the BSA for subjects ages 12 -17 years old, or ≥35% of the BSA 
for subjects ages 2 -11 years old , suitable for topi[INVESTIGATOR_8588] .  Scalp should be excluded from th e BSA 
calculation to determine eligibility during Screening and at Baseline, and for all efficacy assessments . 
3. A vIGA -AD™ score of 3 or greater at Screening and Baseline ( pre-dosing ). 
4. AD present for at least 6 months for subjects ages 6-17 years old or 3 m onths for subjects ages 2 to 5 
years old, confirmed by [CONTACT_222196]/or according to the subject and/or 
caregiver(s) . 
5. Female subjects of childbearing potential who are engaging in sexual activity that could lead to 
pregnancy should use on e of the following acceptable birth control methods while on study and for [ADDRESS_341706] exposure to study drug.    
• Acceptable contraception methods include intrauterine device, hormonal contraceptives, barrier 
method (e.g., condom or diaphragm), o r surgical sterilization of male partner (vasectomy)  
• Subjects who claim abstinence as their method of contraception are allowed  provided they agree 
to use a barrier method (e.g., condom or diaphragm) should they become sexually active from 
Screening to [ADDRESS_341707] dose of study drug  
• Non-child -bearing potential is defined as:  
• premenarchal  
• pre-menopausal females with a documented bilateral tubal ligation, bilateral oophorectomy, 
hysterectomy, or hysteroscopic sterilization  
6. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and 
a negative urine pregnancy test at Baseline (Day 1).  
7. Subject, subject’s parent(s), or legal representative must be capable of giving written informed 
consent, which includes compliance with the requirements and restrictions listed in the consent/assent 
form; written informed consent must be obtained prior to any study related procedures.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341708] who meets any of the following criteria will be excluded and considered ineligible for participation 
in the study:  
1. Concurrent conditions:  
a. Immunocompromised (e.g., lymphoma, acquired immunodeficiency syndrome) or medical history 
of positiv e human immunodeficiency virus antibody at Screening.  
b. Chronic or acute systemic infection requiring treatment with antiparasitics, or antiprotozoals, 
within 4 weeks prior to the Baseline visit.  
c. Chronic or acute systemic bacterial infection requiring trea tment with systemic antibiotics within 
one week prior to the Baseline visit.  
d. Chronic or acute superficial fungal infection requiring treatment with systemic antifungals within 
one week prior to the Baseline visit  
e. Acute active bacterial, fungal, or viral ( herpes simplex, herpes zoster, chicken pox) skin infection 
within one week prior to the Baseline visit; the condition should be completely resolved one week 
prior to Baseline Visit  
f. Significant dermatologic or inflammatory condition other than AD that, in t he Investigator’s 
opi[INVESTIGATOR_1649], would make it difficult to interpret data or assessments during the study.  For example, 
subjects with an active skin condition such as Kaposi's varicelliform eruption, scabies, molluscum 
contagiosum, impetigo, psoriasis, severe acne, connective tissue disorder, or  Netherton's 
syndrome, or any other concurrent active disease.  
g. Concurrent skin lesions in the treatment area or pruritus due to conditions other than AD that, in 
the opi[INVESTIGATOR_689], would either interfere wi th study evaluations or affect the safety of 
the subject.  
2. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  ≥ 2.0 x the upper limit 
of normal (ULN).  
3. Screening total bilirubin > 1.5x ULN; total bilirubin >  1.5x ULN is acceptable if bilirubin is 
fractionated and direct bilirubin < 35%.  
4. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception 
of Gilbert’s syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HB sAg), 
or positive hepatitis C antibody test result, or presence of anti -hepatitis B core antigen (anti -HBc).  
Subjects having a negative HBsAg and a positive anti -HBc may enroll if they have a positive anti -
hepatitis B surface antigen demonstrating natural  immunity.  Subjects with a history of hepatitis C 
virus  infection who were medically cured and have an undetectable viral load are eligible to enroll.  
Subjects with a history of stable non -alcoholic fatty liver disease without evidence of active 
inflamma tion (elevated ALT/AST ≥ 2.[ADDRESS_341709]) or cirrhosis are eligible to enroll.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 30 5. Current or a history of cancer within 5  years except for adequately treated skin basal cell carcinoma, 
cutaneous squamous cell carcinoma or carcinoma in situ of the cervix (surgical excision or 
electrodessication and curettage).  
6. Subjects who would not be considered suitable for topi[INVESTIGATOR_8588] (e.g., those with extensive disease 
involvement over a large BSA who woul d be candidates for systemic therapy).  
7. Use of any prohibited medication or procedure within the indicated period before the Baseline visit.  
NOTE :  Prohibited concomitant medications, therapy, etc. during the defined period are as listed in the 
bullets bel ow.  If a subject requires any of these medications throughout the study period, he/she may 
be excluded from or discontinued from the study, at the discretion of the Investigator and Medical 
Monitor.  
a. From 4 months prior to Baseline until the completion of  the Follow -up visit or study 
discontinuation:  
• DUPI[INVESTIGATOR_24786]® (dupi[INVESTIGATOR_12458] ) injection.  
• Any monoclonal antibody product that becomes approved for AD during the course of the 
trial. 
b. From 28 days prior to Baseline until the completion of the Follow -up visit or discontinuation:  
• Oral, injectable, and suppository preparations of corticosteroids.  Eye drops and nasal 
preparations are allowed.  Inhaled preparations are allowed when used fo r a stable 
condition and stable dose for ≥ 28 days before Screening and are continued at the same 
dose throughout the study.  
• Oral preparations and injections of immunosuppressants (cyclosporine, methotrexate, 
azathioprine, tacrolimus, Janus kinase inhibit ors, etc.).  
• Excessive sun exposure, tanning booth, other ultraviolet light source and phototherapy 
including psoralen and ultraviolet A therapy or is unwilling to minimize natural and 
artificial sunlight exposure.  
• Treatment with antivirals with the except ion of short -term treatment for acute upper 
respi[INVESTIGATOR_76133] (i.e., influenza) or viral suppressive therapy for a history of 
recurrent herpes labialis or genital herpes.  
c. From 14  days prior to Baseline  until the completion of the Follow -up visit  or discontinuation:  
• EUCRISA® (crisaborole) and any other PDE4 inhibitor.  
• Tacrolimus ointment and pi[INVESTIGATOR_71861].  
• Topi[INVESTIGATOR_222151] (e.g.,  fluocinonide, 
triamcinolone acetonide) or super -high potency  (e.g., clobetasol propi[INVESTIGATOR_16847]).  Eye drops 
and nasal preparations are allowed.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 31 • Coal tar products (on the body).  If subject chooses to treat scalp with study drug, then coal 
tar products are prohibited for use on the scalp.  
• Over the counter or herbal medi cines for atopic dermatitis (topi[INVESTIGATOR_222153]). If 
subjects are using emollients, they may continue to use the same emollient on nonlesional 
skin during the study.  Emollients containing salicylic acid are prohibited during the study.  
d. From 7  days prior to Baseline  until the completion of the Follow -up visit or discontinuation:  
• Topi[INVESTIGATOR_222167] (e.g., desonide, hydrocortisone).    
• Oral, injectable, or intravenous antibiotics or antifungal medications.  
• Topi[INVESTIGATOR_222168], topi[INVESTIGATOR_222169], or topi[INVESTIGATOR_222156].  
NOTE:  Oral doxepin is allowed for treatment of depression if subject has been on a stable 
dose (4 weeks) at Screening . 
• Topi[INVESTIGATOR_57961], except for the treatment of follicular events  
• Antihistamines/antiallergics (oral, topi[INVESTIGATOR_222157]):  diphenhydramine, 
chlorpheniramine maleate, hydroxyzine.  
NOTE :  The following antihistamines are allowed from Screening throughout the treatment 
period: loratadine, fexofenadin e hydrochloride, cetirizine hydrochloride.  Subjects  are 
allowed to switch from non -allowed antihistamines during Screening  but must be on a 
stable dose for [ADDRESS_341710] dosing day in the current study:  [ADDRESS_341711] 
(whichever is longer).  
8. A history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the 
Investiga tor’s opi[INVESTIGATOR_1649], may interfere with the subject’s participation in the study, interpretation of 
results, or ability to understand and give informed consent.  
9. Pregnant females as determined by [CONTACT_222190] (Screening) or urine (Baseline) human chorionic 
gonadotropin test.  
10. Lactating females.  
11. History of sensitivity to the study medications, or components thereof or a history of drug or other 
allergy that, in the opi[INVESTIGATOR_24245], contraindicates their participation.  
12. Previous known  participation in a clinical study with tapi[INVESTIGATOR_191752] (previously known as [COMPANY_004]2894512 
and WBI -1001).  
4.[ADDRESS_341712] avoid ultraviolet  light, phototherapy, and e xcessive sun exposure throughout the study.  When 
prolonged exposure cannot be avoided, use of sunscreen products (except on AD lesions) and protective 
apparel are recommended.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 32 4.5 Screening/Baseline Failures   
To determine subject eligibility at Screening and Baseline, a single repeat of tests or procedures may be 
allowed during the screening period at the discretion of the Investigator; the Medical Monitor should be 
consulted if neede d.   
Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently 
enrolled .  A minimal set of screen failure information is required to ensure transparent reporting of screen 
failure subjects to meet the  Consolidated Standards of Reporting Trials publishing requirements and to 
respond to queries from regulatory authorities.  Minimal information includes demography, screen failure 
details, eligibility criteria, and any AEs/S AEs.  
A subject who screen fails may be allowed to re -screen one time at the discretion of the Investigator ; the 
Medical Monitor  should be consulted, if needed . 
4.[ADDRESS_341713] may voluntarily disc ontinue treatment and/or withdraw from participation in this study at any time 
at his/her own request or  may be discontinued from study treatment at any time at the discretion of the 
Investigator for safety, behavioral, compliance, or administrative reason s.  Subjects withdrawn from the study 
will not be replaced.  
4.6.[ADDRESS_341714] will be withdrawn from the study  for any of the following 
reasons:  
• Subject has an AE that is considered to be related to study drug or procedures AND is severe enough 
to warrant treatment discontinuation, as determined by [CONTACT_737] (Section  8.1). 
• Pregnancy  
• Any Grade 3 or 4 AE , based on National Cancer Institute Common Terminology Criteria for Adverse 
Events  (CTCAE) criteria , considered causally related to study drug (Section  8.2.2 ) 
Study drug may be discontinued and the subject withdrawn from the study for any of the following reasons:  
• Subject requires concurrent prohibited medication during the study.  Nonmedicated emollients that do 
not contain salicylic acid may be used on nonlesional skin; emollients should not be applied to lesional 
skin during treatment.  The same emollient should be used throughout the subject’s participation in the 
study.  
NOTE : If, in the opi[INVESTIGATOR_191794], such medication will not 
interfere with the conduct or interpretation of the study or compromise the safety of the subject, then 
the subject may continue to receive stud y drug.  If the subject is permanently discontinued from study 
drug, they may remain in the study for safety assessments as needed, at the discretion of the 
Investigator and Medical Monitor, but they are not eligible to enroll in the open -label , long-term safety 
study . 
• Subject noncompliance  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 33 • Investigator noncompliance  
• Discontinuation of the study at the request of the Sponsor, regulatory agency, or an Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC).  
If a subject meets a withdrawal criteri on during treatment, an Early Termination visit will be required (Section  
7.7). 
4.6.2 Withdrawal Procedures   
The primary reason for the discontinuation of study drug and/or withdrawal from study must be recorded in 
the source document and on the case report form (CRF).  If a subject is  prematurely discontinued from study 
drug, the Investigator must make every effort to perform an Early Termination Visit (Section  7.7) and 
document the primary rea son for withdrawal.  
4.[ADDRESS_341715] to follow -up if he/she repeatedly fails to return to the study site for scheduled 
visits and is unable to be co ntacted by [CONTACT_3452].  The following actions must be taken if a subject fails to 
return to the clinic for a required study visit:  
• The site must attempt to contact [CONTACT_3184]/or caregiver (s) and reschedule the missed visit as soon 
as possible, cou nsel the subject on the importance of maintaining the assigned visit schedule, and 
ascertain whether or not the subject wishes to and/or should continue in the study.  
• Before a subject is deemed lost to follow -up, the Investigator or designee must make ever y effort to 
regain contact [CONTACT_280009]-or caregiver (s) (where possible, [ADDRESS_341716]’s last known mailing address or local equivalent methods).  These 
contact [CONTACT_9300]’s medical record.  
• Should the subject and/or caregiver (s) continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  In this case, the discontinuation 
date will be list ed as the date the certified letter was mailed to the subject.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 35 Subjects and/or caregivers will take the tubes home and self -administer study drug (or have caregiver(s) apply 
if necessary) to affected areas QD, except on clinic visit days when study drug is applied under su pervision at 
the site.  
Subjects will be instructed to apply study drug as follows:  
• QD application to affected areas; subjects or their caregivers are advised  to choose the application 
time they prefer and to apply the study drug at that approximate time ea ch day of study participation. 
Subjects should avoid dosing around midnight to avoid potentially dosing twice in one calendar day.  
• If a subject misses a daily dose, it will be recorded as a protocol deviation. The subject should 
continue dosing the next da y and should not apply more than QD to make up for the missed dose on 
the previous day.  If a dose is missed, the missed dose and the reason for the missed dose should be 
recorded in the daily diary as such. Itch rating can still be recorded in the diary e ven if a daily dose 
was missed  
• On Day 1, study drug application should be avoided at the site of phlebotomy for PK blood draws.  
• Study drug should be applied to dry, clean skin.  
• Study drug may be applied to skin around the eye but avoid direct contact [CONTACT_222199] – study drug is 
not for ophthalmic use.  
• Wash hands after application, unless treating lesions on the hands.  
• Study drug should be applied to all lesions, including newly appearing lesions and lesions that have 
improved during the study.  A body diag ram identifying locations of lesions may be provided to the 
subject and/or caregiver.  
• Subjects are allowed, but not required, to treat scalp lesions with study drug ; however, efficacy 
analyses will not include assessment of AD in this area . 
• If there is res idual cream visible on the disease -affected lesional skin, then the subject and/or caregiver 
should be instructed to continue to lightly rub the cream into the skin until it is no longer visible.  
• If study drug is applied to the subject by [CONTACT_19015], t hat person should thoroughly wash his/her 
hands after application.   
• When dosing at home, subjects and/or caregivers should record the time of study drug application in 
the daily diary.  Itch rating should also be recorded in the diary.  
• Nonmedicated emolli ents that do not contain salicylic acid may be used on nonlesional skin but the 
subject (or caregiver) should wait at least 30 minutes after applying study drug before applying 
nonmedicated emollients; emollients should not be applied to lesional skin duri ng treatment.  The 
same emollient should be used throughout the subject’s participation in the study.  
• On clinic visit days, study drug should be applied in the clinic under the supervision of site personnel . 
NOTE:  The time of the dose and assessments on clinic visit days will depend on the time of the clinic 
visit.  Therefore, the timing of the clinic visit may differ from the subject’s chosen dosing time. The 
intention is to allow flexibility to accommodate subjects’ schedules.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 36 Subjects and/or caregivers  will be instructed/reminded on how to apply study drug at each clinic visit (except 
during the final treatment visit).  
  
 
 
  
 
  
 
 
   
 
 
 
5.2 Randomization/Treatment Assignment   
All subjects will receive tapi[INVESTIGATOR_191753], 1% QD for [ADDRESS_341717] and/or caregiver with detailed instructions concerning 
protocol requirements and use of study drug.  Additionally , subjects and/or caregivers will be asked to 
complete a daily diary with the time of each application of study drug, except on study visit days.  At each 
post-Baseline study visit, study staff will review use of study drug, as applicable, with the subject .  Subject 
compliance will be assessed via study diary completion.  
When subjects are dosed at the site, they and/or their caregiver s will apply the study drug under supervision of 
the study staff.  The date and time of each dose administered in the clinic will be recorded in the source 
documents.  In clinic doses are not recorded in the subject’s daily diary.  The study drug and study subject 
identification should be confirmed at the time of dosing by a member of the study site staff other than the 
person d ispensing the study drug.  
At the time of dispensing study drug to each subject, site personnel will weigh the tubes to be dispensed with 
the cap on and will record the weight of all tubes dispensed at each visit in the drug accountability logs.  
Subjects a nd/or caregivers will be instructed to bring all used and unused tubes with them to each study visit.  
Site personnel will weigh the returned tubes (used and unused) with the cap on and record the weight in the 
drug accountability logs.  If a tube has been  lost, discarded, or forgotten by [CONTACT_423], then the site personnel 
will make a notation of this on the drug accountability logs.  Forgotten tubes should be returned by [CONTACT_222203].  Tubes of study medication dispensed at the mos t recent prior visit which remain 
unopened (the foil cap on the tube remains fully intact/undisturbed) may be re -dispensed to study subjects at 
the current visit.  Unopened tubes may only be re -dispensed once.  Opened, partially used tubes or tubes with 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341718](s).  
5.5 Treatment after the End of the Study   
Subjects will not receive any additional treatment with the study drug from the Sponsor after completion of 
the study (with the exception of eligible subjects who enroll in the  open -label, long -term safety study) be cause 
the indication being studied is not life threatening or seriously debilitating and other treatment options are 
available.  
The Investigator is responsible for ensuring that consideration has been given to the poststudy care of the 
subject’s medical co ndition, whether or not the Sponsor is providing specific poststudy drug.  
5.6 Prior and Concomitant Therapy   
Any medication (including over the counter or prescription medication, vit amins and/or herbal supplements) 
administered to the subject up to [ADDRESS_341719] also 
include name [CONTACT_11889] (generic name, as a general rule), dose, frequency, administration routes, and 
dates of the first and last dose, as applicable.  
The Medical Monitor should be contact[CONTACT_280010].  
5.6.1 Permitted Medications and Nondrug Therapi[INVESTIGATOR_279991] ( Day 28) and that the medication is not a prohibited medication as 
described in the Exclusion Criteria (Section  4.3). 
In the event of skin infection, topi[INVESTIGATOR_222171]; however, study drug  must not be applied to the area until the skin 
infection is healed.  
Nonmedicated emollients that do not contain salicylic acid may be used on nonlesional skin;  but the subject 
(or caregiver) should wait at least [ADDRESS_341720]’s participation in the study.   
NOTE :  Any emollient used during the study must be recorded as a  concomitant medication.   
5.6.2 Prohibited Medications and Nondrug Therapi[INVESTIGATOR_222172] (Section  4.3).  A list of prohibited medications, emollients and nondrug therapi[INVESTIGATOR_222173] a separate document.   
If a subject chooses to treat scalp with study drug, then medicated shampoos that contain coal tar, salicylic 
acid, or hydrocortisone are prohibited for use.   Emollients containing salicylic acid are prohibited.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 38 6 Study Assessments and Procedures   
Study procedures and assessments are summariz ed in the Schedule of Assessments and in Section  6.  
Adherence to the study design requirements, including those specified in the Schedule of Assess ments ( Table 
1) are essential and required for study conduct.  Protocol waivers or exemptions are not allowed, except for 
immediate safety concerns.  
6.1 Demography, Medical History, and Baseline Characteristics   
6.1.1 Demographics   
Demographic information collected will include age, sex, race, ethnicity, and Fitzpatri ck skin type.  
Information on Fitzpatrick skin type can be found in Appendix 2. 
6.1.2 Medical History   
Medical history will be collected to ensure subjects are eligible for participation in the study (per inclusion 
Section  4.2 and exclusi on Section  4.3 criteria).  
Data collected will include month and year of AD diagnosis, allergic conditions, and cardiovascular (CV) 
medical history risk factors  (including height , weight, blood pressure , medical c onditions , and famil y history  
of premature CV disease) and fam ily history  of liver disease.  
As part of the subject’s disease history, all systemic (oral and injectable) medications used by [CONTACT_3433] e subject for 
treatment of AD prior to [ADDRESS_341721]’s medical history . 
6.2 Efficacy Assessments   
To minimize inter -observer variability, Investigators and evaluators/raters will be trained on each of the 
required assessments during an Investigator meetin g, site initiation visit, and/or utilizing online assessments 
before enrolling subjects at their study site.  Only trained evaluators/raters are permitted to perform the 
efficacy assessments.  To the fullest extent possible, the same Investigator (or desig nated evaluator/rater) will 
perform all efficacy assessments for an individual subject throughout the study.  If it is not possible for the 
same evaluator/rater to continue performing assessments, it is recommended that the primary and subsequent 
evaluator /rater both examine and discuss their respective scoring during at least 1  visit.  
6.2.1 Assessments Completed by [CONTACT_10670]   
[IP_ADDRESS]  Validated Investigator Global Assessment   
The vIGA -AD™ of disease severity will be assessed at every clinic visit.  The vIGA -AD™ is a global 
assessment of the current state of the disease.  It is a [ADDRESS_341722] a vIGA -AD™ score of at least 3 or 4 at Screening and the Baseline visit (Day  1).  
Eli Lilly and Company (Lilly) developed the vIGA-AD™ scale for use in clinical trials.  For more 
information on the vIGA -AD™ please refer to Appendix 3 and the website 
http://www.eczemacouncil.org/research/investigator -global -assessment -scale/  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 39 Table  3: Validated Investigator Global Assessment Scale for Atopic Dermatitis   
Score  Category  Definition  
0 Clear  No inflammatory signs of atopic dermatitis (no erythema, no 
induration/papulation, no lichenification, no oozing/crusting).  
Post-inflammatory hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_279992].  
[ADDRESS_341723] clear  Barely perceptible erythema, barely perceptible induration/papulation, and/or 
minimal lichenification.  No oozing or crust ing. 
2 Mild  Slight but definite erythema (pi[INVESTIGATOR_8745]), slight but definite induration/papulation, 
and/or slight but definite lichenification.  No oozing or crusting  
3 Moderate  Clearly perceptible erythema (dull red), clearly perceptible 
induration/papulation, and/or clearly perceptible lichenification.  Oozing and 
crusting may be present.  
4 Severe  Marked erythema (deep or bright red), marked induration/papulation, and/or 
marked lichenification.  Disease is widespread in extent.  Oozing or crusting 
may be present.  
[IP_ADDRESS]  Body Surface Area Affected   
The assessment of the %BSA affected is an estimate of the percentage of total involved skin with AD.  For 
the purpose of clinical estimation,  the total palmar surface of the subject’s palm and digits may be assumed to 
be approximately equivalent to 1%  BSA.  The %BSA affected by [CONTACT_280011] 0%  to 
approximately 100% [scalp excluded ]).  Details on calculation of approximate %BSA invo lvement in each 
subject are provided in Appendix 4.  Percentage BSA is a static assessment made without reference to 
previous scores.   
6.2.[ADDRESS_341724]’s AD based on both lesion severity and the %BSA  affected (Hanifin , 2001).  The EASI is a composite 
score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation , excoriation, and 
lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for % BSA 
involved for each body region relative to the whole body.  A detailed procedure of EASI score calculation is 
provided in  Appendix  4.  The EASI score will be calculated in the CRF based on the subject’s age, the rating 
scores for each region, and the number of handprints involved for each region.  
6.2.[ADDRESS_341725]   
[IP_ADDRESS]  Peak Pruritus Numeric Rating Scale   
The PP NRS is a scale used to quickly assess itch/pruritus severity over a [ADDRESS_341726] 24 hours.  On clinic 
visit days, the PP -NRS will be assess ed in the clinic and not recorded in the diary. For subjects ages 2 to < 12 
years, the PP -NRS will be completed by [CONTACT_40970].   For subjects ages ≥ [ADDRESS_341727].  
An example of the PP -NRS is provided be low. 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 40  
PP-NRS  
On a scale of 0 to 10, with 0 being ’no itch‘ and 10 being ’worst itch imaginable‘, how would you rate your 
itch at the worst moment during the previous 24 hours?  
 
PP-NRS © 2019 Regeneron Pharmaceuticals, Inc. and SAR&D. All rights reserved. Used with permission of 
Regeneron Pharmaceuticals, Inc. and SAR&D  
6.[ADDRESS_341728] signs the Informed Consent Form ( ICF) until 
the final visit/contact [CONTACT_1155].  Additional safety information, including the definition of an AE and 
the methods for recording, evaluating, and assessing causality of AEs and the procedures for completing and 
transmitting SAE reports are provided in Section  8. 
6.3.2 Brief Physical Examination   
A brief physical exam ination will include, at a minimum, assessments of the skin, lungs, cardiovascular  
system, and abdomen (liver and spleen).  Assess for changes in onset of menses (female participants) or 
sexual activity (male or female participants). Determine if there is a need for contraception or barrier use.  
Height and weight will be measured at Screening only.  Investigators should pay special attention to clinical 
signs related to previous serious illness.  
6.3.3 Vital Signs   
Vital signs will be measured before blood collection for clinical laboratory assessments and PK analysis 
(where applicable) and will include measurements of systolic and diastolic blood pressure, pulse rate, and 
body temperature .  Subjects should be in a seated position for at least [ADDRESS_341729] be conducted in accordance with the Study Reference 
Manual or Laboratory Manual and the protocol Schedule of Assessments ( Table 1).  Laboratory requisition 
forms must be completed, and samples must be clearly labeled with the subject number, protocol number, site 
number, and visit date.  Details for the preparation and shipment of samples will be provided by [CONTACT_222206].  Reference ranges for all safety 
parameters will be provided to the site by [CONTACT_91007].  
A list of clinical laboratory tests and parameters is provided in Table 4. 

Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 41 All laboratory tests with values that are considered clinically significantly abnormal during participation in the 
study should be repeated until the values return to normal or baseline.  If such values do not return to normal 
within a period judged reason able by [CONTACT_737], the etiology should be identified, if possible, and the 
Sponsor and Medical Monitor notified.  
Table 4: Laboratory Tests   
Diagnost ic Screening Tests  
• HBsAg  
• Hepatitis C antibody  
• Anti-HBc 
• Anti-HBsa • Pregnancy tests: (serum at Screening and urine at other visits  when performed ; 
women of  CBP only)b 
• At the Investigator’s discretion, subjects may be screened for alcohol and illicit 
drug use. 
Serum Chemistry  
• BUN  
• Creatinine  
• Glucose (fasting not required)  
• Sodium  
• Potassium  
• Chloride  • Total carbon dioxide  
• Calcium  
• AST  
• ALT  
• Alkaline phosphatase  • Uric acid  
• Total bilirubin (+fractionated if 
required)  
• Total protein  
• Albumin  
Hematology  
• Platelet count  
• RBC count  
• WBC count (absolute)  
• Reticulocyte count  
• Hemoglobin  
• Hematocrit  • RBC Indices : 
• MCV  
• MCH  
• MCHC  
• Reticulocyte percentage  • WBC Differential:  
• Neutrophils  
• Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
Urinalysis  
• Specific gravity  
• Microscopic examination (if blood or protein is abnormal  • Dipstick:   pH, Glucose, Protein, 
Blood Ketones  
a. Reflex test: a negative HBsAg and a positive anti -HBc may enroll if the y have a positive  anti-HBs demonstrating natural 
immunity  
b. Pregnancy tests  should be administered based on CBP, which may change after the start of the study (e .g. a premenarchal female 
subject experiences menarche or a female subject ceases to meet the criteria of CBP)  
ALT  = alanine aminotransferase; Anti -HBc = anti -hepatitis B core antigen; Anti -HBs = anti -hepatitis B surface antigen; 
AST  = aspartate aminotransferase; BUN  = blood urea nitrogen; CBP  = child -bearing potential; HBsAg = hepatitis B surface 
antigen; MCH  = mean corpuscular hemoglobin; MCHC  = mean corpuscular hemoglo bin concentration; MCV  = mean corpuscular 
volume; RBC  = red blood cell(s); WBC  = white blood cell(s).  
6.3.5 Investigator Ass essed  Local Tolerability Scale   
At each specified study visit , the Investigator (or qualified evaluator) will assess the presence and overall 
degree of irritation at the application sites according to a 5 -point LTS.  The score will ideally represent an 
“average” across all application sites.  To the fullest extent p ossible, the same Investigator (or designated 
evaluator) will perform all tolerability assessments for an individual subject throughout the study.  If the 
subject is applying study drug to “sensitive areas”, a separate LTS will be used to assess the degree  of 
irritation for each of these areas  where study drug is being applied .  The sensitive areas that will be assessed 
are face, neck, skin folds, axilla, inframammary, anal crux, and genitalia.  An example of the LTS is shown  in 
Appendix 5.  The LTS should be completed pre -dose at Baseline/Day 1, Day 8, and Day 28 when other 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341730] is currently receiving study drug (i.e. has applied at least one application in the 
last 48 hours).  
6.[ADDRESS_341731] will be considered an overdose.  
Ingestion of a 30 -gram tube of tapi[INVESTIGATOR_191753], 1% would result in an oral dose of 300  mg. 
The Sponsor does not recommend specific treatment f or an overdose; however, in the event of an overdose, 
the Investigator (or treating physician) should do the following:  
• Contact [CONTACT_191841]  
• Closely monitor the subject for AEs/SAEs and laboratory abnormalities  
• Provide general sympt omatic treatment as necessary  
• Document the quantity of the excess dose as well as the duration of the overdosing.  
• If the Medical Monitor requests a plasma sample for PK analysis, then a blood sample for PK 
should be obtained within [ADDRESS_341732].  
6.5 Pharmacokinetics   
Blood samples for PK analysis of tapi[INVESTIGATOR_191753], 1% will be collected at timepoints indicated in the 
Schedule of Assessments ( Table 1) and Section 7.  Blood samples for PK should not be collected from any 
anatomic site where study drug has been applied in order to minimize potential contamination.   The actual 
date and time of each blood sa mple collection will be recorded as well as the date and time of the last dose of 
study drug prior to sample collection.  Collection, processing, storage, and shippi[INVESTIGATOR_279993] . 
Concentratio ns of tapi[INVESTIGATOR_222176] a validated bioanalytical method.  
Raw data will be archived at the bioanalytical site.  From the plasma concentration time data on Day 1, the 
following primary PK parameters will be determined:  A UC 0-last, Cmax, tmax, and t last. 
An analysis of the PK data will be performed after 25% of the subjects (n=9) have completed the study to re -
assess the PK sampling scheme with the potential to eliminate the [ADDRESS_341733] can only be contact[CONTACT_3012], the following should be assessed or performed:  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 43 • AEs 
• Concomitant Medications  
• Reminder to complete diary  
• Instruction not to discard  empty tubes of study drug  
If the subject  or caregiver  has video capabilities, the following items should be assessed or performed:  
• AEs 
• Concomitant Medications  
• vIGA -AD™ assessment (exclu ding subject’s scalp)  
• %BSA affected calculation (excluding subject’s scalp)  
• EASI  (excluding subject’s scalp)  
• LTS (Investigator assessment)  
• Application of study drug  by [CONTACT_423]  
• Completion of the PP -NRS  itch scale – The subject can verbally indicate the answer which the study 
coordinator will document in the source docume nt.  
• Reminder to complete diary  
• Instruction not to discard empty tubes of study drug  
The reason that assessments cannot be completed during a virtual assessment (i.e., labs, vital signs, physical 
exams, etc.) must be noted (e.g., COVID -19) and the missed assessments will be recorded as protocol 
deviations. 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 44 7 Timing of Procedures and Assessments   
This section lists the procedures and assessment s to be performed at scheduled timepoints during the study as 
outlined in the Schedule of Assessments ( Table 1).  Information on study procedures and ass essments is 
provided in Section  6. 
• Any change in timing or any addition of a timepoint(s) for any planned study assessment must be 
documented in a “N ote to File,” which is approved by [CONTACT_280012]; this will NOT constitute a protocol 
amendment.  
• The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring 
scheme or amendment of the  ICF. 
NOTE:  Assessments and procedures should be performed  pre dose on clinic visit days.  
7.1 Visit 1; Screening Period (Day -30 to Day -1)  
After the subject has signed the consent/assent form, potential study subjects will undergo Screening 
procedures and assessments to confirm eligibility to participate in the study.  Screening assessments will 
include the following:  
• Demography rec ording  
• Fitzpatrick skin typ e 
• Brief physical examination (including height and weight [BMI will be calculated in the CRF ]) 
• Medical history recording (including all medications up to 30 days prior to screening and all systemic 
[oral and injectable] medications used by [CONTACT_280013] 30 days before 
screening)  
• Serum pregnancy test (females of child -bearing potential)  
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic tests)  
• Urina lysis 
• Vital signs measurements  
• Blood sample collection for PK analysis (if the subject is eligible)  
• AE recording (from the time the ICF is signed)  
• Concomitant medication recording (including emollients)  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp ) 
To determine subject eligibility at Screening, a single repeat of tests or procedures may be allowed at the 
discretion of the Investigator.  The Medical Monitor should be consulted if needed.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 45 7.2 Visit 2; B aseline (Day  1)  
On Day 1, subjects will be reassessed to confirm continued eligibility to participate in the study.  All subjects 
who continue to meet study eligibility criteria will be enrolled and receive  treatment.  
The following additional procedures and assessments will be performed at the Baseline Visit : 
• Brief physical exam   
• Changes to medical history   
• Urine pregnancy test (females of child -bearing potential)   
• Vital signs mea surement   
• Dispense study drug   
• Provide instructions on how to apply study drug   
• Dispense study drug subject diary and PP -NRS diary   
• Study drug application under supervision  
• Blood sample collection for PK analysis   
• AE recording   
• Concomitant medication reco rding   
• vIGA -AD™ score (excluding subject’s scalp)   
• %BSA affected calculation (excluding subject’s scalp)   
• EASI (excluding subject’s scalp)   
• LTS assessment by [CONTACT_10670]   
• Assessment of itch (PP -NRS)   
7.3 Visit 3; Week  1 (Day  8 ±2 Days)   
The following procedures and assessments will be performed at Visit 3:  
• Brief physical exam  
• Vital signs measurement  
• Collect and dispense study drug  
• Review instructions on how to apply study drug  
• Collect study drug subject diary and PP -NRS diary and review for compliance  
• Dispense study drug subject diary and PP -NRS diary  
• Study drug application under supervision  
• AE recording  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 46 • Concomitant medication recording  
• vIGA -AD™ score  (excludin g subject’s scalp ) 
• %BSA affected calculation  (excluding subject’s scalp ) 
• EASI  (excluding subject’s scalp ) 
• LTS assessment by [CONTACT_10670]  
• Assessment of itch (PP -NRS)  
7.[ADDRESS_341734] at Day 15 ±[ADDRESS_341735] AEs and concomitant medication use.  Subjects s hould be reminded to complete their daily 
diary and bring it with them to the next clinic visit.  
7.5 Visit 4; Day 28 ±2 Days   
The following procedures and assessments will be performe d at Visit 5:  
• Brief physical exam     
• Urine pregnancy test (females of child -bearing potential)     
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic tests)  
• Urinalysis     
• Vital signs measurement     
• Collect study d rug    
• Collect study drug subject diary and PP -NRS diary and review for compliance        
• Blood sample collection for PK analysis     
• AE recording     
• Concomitant medication recording     
• vIGA -ADTM score (excluding subject’s scalp)     
• %BSA affected calculation  (excluding subject’s scalp)     
• EASI (excluding subject’s scalp)     
• LTS assessment by [CONTACT_10670]     
• Assessment of itch (PP -NRS)    
• Enrollment in open -label, long -term safety study (optional)   
  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 47 7.6 Visit 5; Follow -Up (Day 35 ±3 Days )  
Subjects who do not enroll in the open -label long -term safety study will return to the study site 7 -10 days after 
Day 28 to complete follow -up assessments as follows : 
• Brief physical examination  
• If needed , blood sample collection for clinical laboratory tests  
• If needed, urinalysis  
• Vital signs measurement  
• AE recording  
• Concomitant medication recording  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation  (excluding subject’s scalp ) 
• EASI  (excluding subject’s scalp ) 
7.7 Early Termination Visit   
Subjects who withdraw early from the study will be asked to return to the study site to complete Early 
Termination assessment s as follows : 
• Brief physical examination     
• Urine pregnancy test (females of child -bearing potential)     
• Blood sample collection for clinical laboratory tests     
• Urinalysis     
• Vital signs measurement     
• Collect study drug     
• Collect study drug subject diary and PP -NRS diary and review for compliance     
• AE recording     
• Concomitant medication recording     
• vIGA -AD™ score (excluding subject’s scalp)     
• %BSA affected calculation (excluding subject’s scalp)     
• EASI (excluding subject’s scalp)  
7.[ADDRESS_341736] an unscheduled visit for AE follow -up, study drug dispensation, make -up for a missed 
visit, or other reason.  The following assessments may be performed as ne eded : 
• Brief physical examination  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 48 • Urine pregnancy test (females of child -bearing potential)  
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic tests)  
• Urinalysis  
• Vital signs measurement  
• Dispense and / or collect st udy drug  
• Review instructions on how to apply study drug  
• AE recording  
• Concomitant medication recording  
• Dispense and / or collect subject diaries  
• vIGA -ADTM score  (excluding subject’s scalp ) 
• %BSA affected calculation  (excluding subject’s scalp )  
• EASI  (excludi ng subject’s scalp ) 
• Assessment of itch (PP -NRS)  
• Review subject diaries for treatment compliance  
7.[ADDRESS_341737] has completed the Follow up Visit (if subject does 
not enroll in the separate open -label , long-term safety study) OR the last active subject has completed the 2 7 
days of treatment in this study (if subject is eligible and enrolls in the separate open -label , long-term safety 
study).  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341738] (AES Is).  At each visit/contact, subjects should 
be questioned in a general way so as not to introduce bias in detecting AEs and/or SAEs.  Open -ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about AE occurrence.  
Investigators are not obligated to actively seek AEs or SAEs in former study subjects.  However, if the 
Investigator learns of any SAE, including a death, at any time after a subject has been discharged from the 
study, and he/she considers the event reasonably  related to the study drug or study participation, the 
Investigator should promptly notify the Sponsor.  
A narrative will be written and included in the Clinical Study Report  for all SAEs and AESIs, and for all AEs 
that lead to study discontinuation.  
8.1.[ADDRESS_341739].  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.  
Events meeting the  definition of an AE include:  
• Any abnormal laboratory test results (hematology, clinical chemistry) or other safety assessments 
(e.g., vital signs measurements), including those that worsen from Baseline, and felt to be clinically 
significant in the medica l and scientific judgment of the Investigator  
• Exacerbation of a chronic or intermittent pre -existing condition (e.g., plaque psoriasis) including either 
an increase in frequency and/or intensity of the condition  
• For skin -related AEs, it should be noted whe ther or not the event is in the area of active application of 
study drug, and/or if spreading beyond the application site.  
• New conditions detected or diagnosed after study drug administration even though it may have been 
present prior to the start of the s tudy 
• Signs, symptoms, or the clinical sequelae of a suspected interaction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a 
concomitant medication (overdose per se will not be reported as an AE/SAE)  
• "Lack of effica cy" or "failure of expected pharmacological action" per se will not be reported as an AE 
or SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, symptoms, 
and/or clinical sequelae resulting from lack of efficacy will be r eported as AE or SAE if they fulfill the 
definition of an AE or SAE.  
Events that do not  meet the definition of an AE include:  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341740]’s condition  
The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being 
studied, unless more severe than expected  for the subject’s condition  
Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an 
AE 
Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a 
hospi[INVESTIGATOR_307])  
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the start of 
the study that do not worsen  
8.1.2 Definition of Serious Adverse Event   
If an event is not an AE per Section  8.1.1 , then it cannot be an SAE even if serious conditions are met (e.g., 
hospi[INVESTIGATOR_1080]/symptom s of the disease under study, death due to progression of disease, etc.).  
• An SAE is any untoward medical occurrence that, at any dose:  
• Results in death  
• Is life -threatening  
­ The term “life threatening” refers to an event in which the subject was at risk of d eath at the 
time of the event.  It does not refer to an event, which hypothetically might have caused death, 
if it were more severe.  
• Requires hospi[INVESTIGATOR_1081]  
­ In general, signifies that the subject has been detain ed (usually involving at least an overnight 
stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have 
been appropriate in the physician’s office or outpatient setting.  Complications that occur 
during hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_13270], the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or 
was necessary, the AE should be considered serious.  
­ Hospi[INVESTIGATOR_181861] a pre -existing condition that did not worsen from 
Baseline is not considered an AE.  
• Results in disability/incapacity:  a substantial disruption of a person’s ability to conduct normal life 
functions.  
­ This definition is not intended to include exper iences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(e.g., sprained ankle) which may interfere or prevent everyday life functions but do not 
constitute a substantial d isruption.  
• Results in a congenital anomaly/birth defect  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341741] been identified as AEs of particular 
clinical importance and will be reported as AESIs in thi s study.   
In each case study drug may be continued or discontinued, based on Investigator judgment, and may be 
restarted when the event resolves.  In addition, the following information should be collected for each of these 
AESIs : 
Contact [CONTACT_222211], time to onset, duration, size, associated symptoms (itching, burning, 
pain), severity (mild, moderate, severe), concomitant medications used to treat, action taken with study drug 
and photograph the affected site (if pos sible).  If the subject contacts the study site to report significant skin 
irritation at or near the site of study drug application between study visits, the subject should be brought in for 
an unscheduled visit, if possible . 
Headache  
The study site should  collect time to onset, duration, severity (mild, moderate, severe),  location (e.g., frontal, 
temporal, occipi[INVESTIGATOR_307], diffuse) . 
Follicular Event  
The study site should collect the location, duration, size, associated signs and symptoms (itching, burning, 
pain erythema ), severity (mild, moderate, severe), describe morphology [scale (keratotic/cornified) or no scale 
(non-keratotic/non -cornified)] , time to onset, and photograph the affected site (if possible).  Additional 
information regarding management of follic ulitis is provided in  Section [IP_ADDRESS].4 . 
In particular, the term ‘folliculitis’ may not correctly describe the morphology of the observed local follic ular 
events as these appear to be more consistent with a keratoses pi[INVESTIGATOR_22785] -like follicular based papule. Tapi[INVESTIGATOR_222179], including involucrin, hornerin, and filaggrin and increased 
cornification at, and subsequent m echanical occlusion of, the follicular ostia has been suggested to be a 
potentially on target mechanism by [CONTACT_222212][INVESTIGATOR_191753]. Additional morphologic description will help to more fully and appr opriately characterize 
these follicular events.  
Possible descriptors include, but are not limited to:  
• Folliculitis  
­ Non-inflammatory  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 52 ­ Inflammatory  
• Milia  
­ Non-inflammatory  
­ Inflammatory  
• Keratosis pi[INVESTIGATOR_22785]  
­ Non-inflammatory  
­ Inflammatory  
Additional AESIs may b e identified during the evaluation of safety data for the Clinical Study Report.    
8.2 Classification of Adverse Events   
8.2.1 Assigning Severity Rating for Adverse Events   
[IP_ADDRESS]  Criteria for Determining Adverse  Event Severity   
The Investigator will make an assessment of the sev erity of each AE and SAE according to the National 
Cancer Institute CTCAE, v. 5.0,  2017.  For terms not specified with the CTCAE, the criteria in Table 5 should 
be used to determine the grade severity.  
Table  5: Criter ia for Determining the Grade/Severity of Adverse Event Terms Not Specified by 
[CONTACT_280014]  
1 Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; intervention not indicated  
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate instrumental activities of 
daily livinga 
3 Severe or medically significant but not immediately life-threatening; hospi[INVESTIGATOR_48622]; disabling; limiting self -care activities of daily livingb 
4 Life threatening consequences; urgent intervention indicated  
[ADDRESS_341742] ivities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
b. Self -care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking medicat ions, and 
not bedridden.  
CTCAE  = Common Terminology Criteria for Adverse Events.  
 
AE severity should be recorded in the appropriate section of the AE CRF  and in the subject’s source 
documents.  
[IP_ADDRESS]  Toxicity Management Criteria   
[IP_ADDRESS].[ADDRESS_341743] study 
withdrawal evaluations completed.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 53 [IP_ADDRESS].2  Grade 3  Adverse Event   
Subjects who develop a Grade 3  AE should be managed as follows:  
• If the Investigator has compelling evidence that the Grade [ADDRESS_341744], then dosing may continue after discussion with the M edical Monitor.  
• Subjects who develop a Grade [ADDRESS_341745] withdrawal study evaluations completed.  
[IP_ADDRESS].[ADDRESS_341746] withdrawal study evaluations 
completed.  
[IP_ADDRESS].[ADDRESS_341747] not required nor resulted in the need for intervention, s everal approaches 
can be employed to mana ge those patients with folliculitis who may be symptomatic including temporary 
interruption of study drug  use at sites of folliculitis and/or the local application to affected areas of topi[INVESTIGATOR_222181] 12% lactic acid lotion, 5-10% urea cream s or lotions.  
[IP_ADDRESS].5  Other Management Criteria   
The Medical Monitor should be notified if any of the following occur:  
• Severe signs or symptoms, or significant changes in any of the safety assessments, that put the 
safety of the subject at risk (e.g., laboratory tests or vital signs, etc.) as judged by [CONTACT_737].  
8.2.2 Assigning Causal Relationship to Study Drug   
The Principal Investigator [INVESTIGATOR_11637] -Investigator is to make the causality assessment.  The reasonable possibility 
of the relationship of an AE to study drug is to be assessed with careful medical consideration at the time of 
evaluation of an AE.  The followin g definitions are to be used for the relationship of the adverse event to 
study drug:  
• Related :  A clinical event, including laboratory test abnormality, with a temporal relationship to 
study drug administration that makes a causal relationship plausible, u nlikely attributed to 
concurrent disease or other drugs or chemicals, and that follows a clinically reasonable response 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 54 on re -administration (rechallenge) or withdrawal (dechallenge), although information on drug 
withdrawal may be lacking or unclear.  
• Not r elated :  A clinical event, including laboratory test abnormality, with a temporal relationship 
to study drug administration that makes a causal relationship improbable and/or in which other 
drugs, chemicals, or underlying disease provide a plausible explan ation.  
Any AEs /SAEs assessed as related to study participation (e.g., protocol -mandated procedures, invasive tests, 
or change in existing therapy) or related to study drug will be recorded from the time a subject consented to 
participate in the study up t o and including any follow -up contact.  
All AEs, whether related to study drug or not, must be fully and completely documented on the AE page of 
the CRF and in the subject’s clinical record.  In the event a subject is withdrawn from the study because of an 
AE, the primary reason for withdrawal (i.e., due to an AE) must be recorded on the CRF as such.  
8.3 Time Period and Frequency for Event Assessment and Follow -Up  
8.3.1 Adverse Event Reporting   
All AEs will be collected from the time of signed informed consent until the final visit.  
Any AEs assessed as related to study participation (e.g., protocol -mandated pr ocedures, invasive tests, or 
change in existing therapy) will be collected from the time a subject consented to participate in the study up to 
and including any follow -up contact.  
All SAEs will be recorded in the CRF and reported to the Sponsor within 24  hours via email or phone (refer 
to the Medical Monitor / Sponsor Information Page  for contact [CONTACT_3031]) (see Section  8.4). 
8.3.2 Follow -Up of Adverse Events   
After the initial AE/SAE report, the Investigator is required to proa ctively follow each subject at subsequent 
visits/contacts.  All SAEs and nonserious AEs will be followed until resolution, until the condition stabilizes, 
until the event is otherwise explained, or until the subject is lost to follow -up. 
The Investigator w ill assess the outcome of each AE using the following criteria:  
• Recovered/Resolved :  The event has improved or subject recuperated.  
• Recovered/Resolved with sequelae :  The subject has recuperated but retained pathological 
conditions resulting from the prior  disease or injury.  
• Recovering/Resolving :  The event is improving.  
• Not recovered/Not resolved :  The event has not improved or subject recuperated.  
• Unknown :  The outcome of the event is not known, not observed, not recorded, or refused.  
• Fatal :  Termination of life as an outcome of the AE.  
8.[ADDRESS_341748] igator determines that an AE meets the protocol definition of an SAE during the study, he/she 
must notify the Sponsor using an SAE Report Form within 24  hours of the study site personnel’s 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 55 knowledge of the event , regardless of the Investigator assessment o f the relationship of the event to study 
drug.  Relevant information will be entered on the AE page and on all other applicable pages of the CRF; 
source documentation should not be sent with the SAE Report Form unless requested.  
Follow -up information recei ved on SAEs should be emailed or faxed to the Sponsor within 1  business day of 
receipt (refer to Medical Monitor / Sponsor Information Page   for contact [CONTACT_82753]).  This information 
should be included on a follow -up SAE form and filed with the original SAE information.  
All SAEs will be followed until resolution, until the condition stabilizes, until the event is otherwise 
explained, or until the subject i s lost to follow -up. 
The completed SAE Report form should be submitted via email or fax to the SAE Reporting Contact [CONTACT_280015] / Sponsor Information Page  of this protocol.  
Do not delay reporting a suspected SAE in order to o btain additional information.  Any additional 
information, if collected, can be reported as a follow -up to the initial report.  
8.4.2 Regulatory Reporting Requirements for Serious Adverse Events   
Prompt notification by [CONTACT_222215] (even for non -interventional post -marketing 
studies) is essential so that legal obligations and ethical responsibilities towards the safety of subjects and the 
safety of a product und er clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory 
agencies about the safety of a product under clinical investigation.  The Sponsor will comply with 
country -specific  regulatory requirements relating to safety reporting to the regulatory authority, IRB/IEC, and 
Investigators.  
Investigator safety reports are prepared for suspected unexpected serious adverse reactions according to local 
regulatory requirements and are fo rwarded to Investigators as necessary.  
An Investigator who receives an Investigator safety report describing a SAE(s) or other specific safety 
information (e.g., summary or listing of SAEs) from the Sponsor will file it with the Investigator’s Brochure 
and will notify the IRB/IEC, if appropriate, according to local requirements.  
8.[ADDRESS_341749] information can be found on the Medical 
Monitor / Sponsor Information Page  of this protocol, within [ADDRESS_341750] will also be followed to determine the outcome of the pregnancy.  Information on the status of the 
mother and child will be forwarded to the Sponsor.  Generally, follow -up will be no longer than 6  to 8 weeks 
following the estimated delivery date.  Any premature termination of the pregnancy will be reported.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 56 Any SAE occurring in association with a pregnancy brought  to the Investigator’s attention after the subject 
has completed the study and considered by [CONTACT_222216]’s representative.  
The Investigator must attempt to c ollect pregnancy information on any female partners of male study subjects 
who become pregnant while the subject is enrolled in the study.  Pregnancy information must be reported to 
the Sponsor or the Sponsor’s representative as described above.  The partn er will also be followed to 
determine the outcome of the pregnancy.  Information on the status of the mother and child will be forwarded 
to Sponsor or the Sponsor’s representative.  Generally, follow -up will be no longer than [ADDRESS_341751] imated delivery date.  Any premature termination of the pregnancy will be reported on the 
Pregnancy Report Form. 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341752] initials will not be collected or transmitted to the Sponsor.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 58 10 Statistical Considerations and Data Analyses   
This study will evaluate the safe ty, tolerability, PK, and efficacy of tapi[INVESTIGATOR_191753], 1% in pediatric subjects 
with AD . 
10.1 General Considerations   
All study data will be summarized overall and by [CONTACT_551] (2 -6 years old, 7 -11 years old, and 12 -17 years 
old) using descriptive statistics.  Categorical variables will be reported using frequency and percentage (e .g., 
gender, race).  Continuous variables will be reported using number of subjects, mean, standard deviati on 
(SD), median, minimum, and maximum.  All efficacy and safety data will be listed by [CONTACT_1130] . 
10.[ADDRESS_341753] evaluable concentration -time data for analysis will 
be included in the PK population.  A sample that is below the quantification limit (BQL) of the assay is 
considered evaluable.  
10.4 Planned Analyses   
All safety, tolerability, PK, and efficacy measures over the course of the study will be presented.  Details of 
planned analyses will be de scribed in the Statistical Analysis Plan (SAP).  
10.4.[ADDRESS_341754].  No formal 
statistical comparisons will be made for safety data.  
The number and proportion of subjects with TEAEs will be summarized by [CONTACT_9313], and preferred 
term for all TEAEs, all TEAEs considered by [CONTACT_66325], all SAEs, and all 
TEAEs leading to study drug discontinuation.   
Laboratory values will be classified as normal, low or high based on normal ranges supplied by [CONTACT_43100].  Changes from baseline in abnormality status will be summarized using shift tables.  For 
quantitative laboratory measures, observed values and changes from baseline will be summarized 
descriptively.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 59 Observed vital sign values (s ystolic and diastolic blood pressure, pulse rate, and body temperature) and 
change from baseline in vital signs will be summarized similarly to the laboratory values.    
LTS scores will be summari zed by [CONTACT_765] . 
10.4.[ADDRESS_341755], day, and time; summaries will be presented by [CONTACT_85340].  
Unles s stated otherwise, descriptive summaries for continuous variables will include n, mean, SD, median, 
minimum, and maximum.  If data permit, PK parameters (AUC 0-last, Cmax, tmax, and t last) will be derived using 
non compartmental methods based on the actual  sampling times recorded in the study . 
10.4.4  Efficacy Anal yses  
All efficacy analyses will be based on the Safety population.  The efficacy endpoints are as follows:  
• Change in vIGA -AD™ score from Baseline at each study visit  
• Proportion of subjects  who have a vIGA -AD™ score of clear or almost clear (0 or 1) at each study 
visit 
• Proportion of subjects with ≥50% improvement in EASI score from Baseline at each study visit  
• Proportion of subjects with ≥75% improvement in EASI score from Baseline at each study visit  
• Proportion of subjects with ≥90% improvement in EASI score from Baseline at each study visit  
• Mean change and percent change in EASI score from Baseline at each stu dy visit  
• Mean change and percent change in %BSA affected from Baseline at each study visit  
• Mean change and percent change in BSA  x vIGA -AD™ values from Baseline at each study visit  
• Proportion of subjects with a Baseline PP -NRS score ≥ 4 who achieve ≥ 4-point reduction in the 
PP NRS from Baseline at each study visit  
• Proportion of subjects ≥ 12 years old with a Baseline PP -NRS score ≥4 who achieve a ≥4 point 
reduction from Baseline at each study visit  
• Proportion of subjects 2 to < 12 years old with a Baseline  PP-NRS score ≥4 who achieve a ≥4 
point reduction from Baseline at each study visit  
• Mean change in PP -NRS score from Baseline at each study visit  by [CONTACT_551]  
10.5 Interim Analyses   
No formal interim analyses will be performed, however the study team may review PK and safety data on an 
ongoing basis.  This includes an analysis of the PK data after 25% of the subjects (n=9) have completed the 
study to re -assess the PK sampling scheme wit h the potential to eliminate the [ADDRESS_341756] -dose blood draw.  If 
require d, changes to the protocol will be made through a protocol amendment . 
10.6 Handling of Missing Data   
No imputations will be made for missing values.  Summaries will be based on observed data only . 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 60 11 Responsibilities   
11.1 Investigator Responsibilities   
11.1.1  Good Clinical Practice   
The Investigator will ensure that this study is conducted in accordance with the principles of the “Declaration 
of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South Africa), International 
Conference on Harmonization guidelines, or with the laws and regulations of the country in which the 
research is conducted, whichever affords the greater protect ion to the study subject.  For studies conducted 
under a [LOCATION_002] Investigational New Drug Application, the Investigator will ensure that the basic 
principles of “Good Clinical Practice,” as outlined in 21  Code of Federal Regulations (CFR) 312, subpar t D, 
“Responsibilities of Sponsors and Investigators,” 21  CFR, part 50, 1998, and 21  CFR, part 56, 1998, are 
adhered to.  These standards are consistent with the requirements of the European Community Directive 
2001/20/EC.  
Since this is a “covered” clinica l trial, the Investigator will ensure that 21  CFR, Part 54, 1998, is adhered to; a 
“covered” clinical trial is any “study of a drug or device in humans submitted in a marketing application or 
reclassification petition subject to this part that the applican t or Food and Drug Administration relies on to 
establish that the product is effective (including studies that show equivalence to an effective product) or that 
make a significant contribution to the demonstration of safety.”  This requires that Investigat ors and all sub -
Investigators must provide documentation of their financial interest or arrangements with the Sponsor, or 
proprietary interests in the drug being studied.  This documentation must be provided before participation of 
the Investigator and any  sub-Investigator.  The Investigator and sub -Investigator agree to notify the Sponsor 
of any change reportable interests during the study and for [ADDRESS_341757]/Independent Ethics Committee Approval   
This protocol and any accompanying material to be provided to the subje ct (such as advertisements, subject 
information sheets, or descriptions of the study used to obtain informed consent) will be submitted by [CONTACT_280016].  Approval from the IRB or IEC must be 
obtained be fore starting the study and should be documented in a letter to the Investigator specifying the 
protocol number, protocol version, protocol date, documents reviewed, and date on which the committee met 
and granted the approval.  
Any modifications made to th e protocol after receipt of IRB or IEC approval must also be submitted to the 
IRB or IEC for approval before implementation.  
11.1.3  Informed Consent/Assent   
The Investigator is responsib le for obtaining written informed consent/assent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and potential hazards of 
the study and before undertaking any study -related procedures.  The Inve stigator must utilize an IRB - or IEC -
approved consent form for documenting written informed consent.  Each informed consent/assent will be 
appropriately signed and dated by [CONTACT_29159]’s legally authorized representative and the person 
obtai ning consent.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341758] assure that subjects’ anonymity will be strictly maintained and that their identities are 
protected from unauthorized parties.   Only subject number, date of birth, and an identification code (i.e., not 
names) should be recorded on any form or biological sample submitted to the Sponsor, IRB or IEC, or 
laboratory.  The Investigator must keep a screening log showing codes, names, an d addresses for all subjects 
screened and for all subjects enrolled in the trial.  
The Investigator agrees that all information received from the Sponsor, including but not limited to the 
Investigator Brochure, this protocol, CRFs, the investigational new d rug, and any other study information, 
remain the sole and exclusive property of the Sponsor during the conduct of the study and thereafter.  This 
information is not to be disclosed to any third party (except employees or agents directly involved in the 
conduct of the study or as required by [CONTACT_2371]) without prior written consent from the Sponsor.  The Investigator 
further agrees to take all reasonable precautions to prevent the disclosure by [CONTACT_280017] e into the public domain.  
11.1.[ADDRESS_341759] 
the following 2  categories: (1) Investigator’s study file, and (2) subject clinical source documents.  
The Investigator’s study file will contain the pro tocol/amendments, CRF and query forms, IRB or IEC and 
governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and 
authorization forms, and other appropriate documents and correspondence.  
The required source data sh ould include at least the following information for each subject:  
• Subject identification (name, date of birth, gender)  
• Documentation that subject meets eligibility criteria, ie, history, physical examination, and 
confirmation of diagnosis (to support inclu sion and exclusion criteria)  
• Participation in trial (including trial number)  
• Trial discussed and date of informed consent  
• Dates of all visits  
• Documentation that protocol -specific procedures were performed  
• Results of efficacy parameters, as required by [CONTACT_760]  
• Start and end dates (including dose regimen) of trial medication (preferably drug dispensing and 
return should be documented as well)  
• Record of all adverse events and other safety parameters (start and end date, and preferably 
including causality and intensity)  
• Concomitant medication (including start and end dates, dose if relevant; dose changes should be 
recorded ) 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 62 • Date of trial completion and reason for early discontinuation, if applicable  
All clinical study documents must be retained by [CONTACT_280018] [ADDRESS_341760] approval 
of a marketing application in an ICH region (i.e., [LOCATION_002], Europe, or Japan) and until there are no 
pending or contemplated marketing applications in an ICH region; or, if no application is file d or if the 
application is not approved for such indication, until [ADDRESS_341761] enrolled, a case report form (CRF) must be completed and signed by [CONTACT_737].  This 
also applies to records for th ose subjects who fail to complete the study.  If a subject withdraws from the 
study, the reason must be noted on the CRF.  If a subject is withdrawn from the study because of a treatment -
limiting adverse event, thorough efforts should be made to clearly do cument the outcome.  
11.1.7  Drug Accountability   
The Investigator or designee (i.e., pharmacist) is responsible for ensuring adequate accountability of all used 
and unused investigational  medicinal product.  This includes acknowledgment of receipt of each shipment of 
study product (quantity and condition), subject dispensing records, and returned or destroyed study product.  
Dispensing records will document quantities received from the Spo nsor and quantities dispensed to subjects, 
including kit number, date dispensed, subject identifier number, and the initials of the person dispensing the 
medication.  
At study initiation, the monitor will evaluate the site’s procedure for investigational me dicinal product 
disposal/destruction in order to ensure that it complies with the Sponsor requirements.  At the end of the 
study, following final drug inventory reconciliation by [CONTACT_2037], the study site will dispose of and/or 
destroy all unused investi gational medicinal product supplies, including empty containers, according to these 
procedures.  If the site cannot meet the Sponsor’s requirements for disposal, arrangements will be made 
between the site and the Sponsor or its representative for destructi on or return of unused investigational 
medicinal product supplies.  
All drug supplies and associated documentation will be periodically reviewed and verified by [CONTACT_280019].  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341762] be obtained bef ore changes can be implemented.  
11.2.2  Study Report and Publications   
A clinical study report will be prepared and provided to the regulatory agency(ies).  The Sponsor will ensure 
that t he report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study 
Reports (ICH E3).  Note that an abbreviated report may be prepared in certain cases.  
After conclusion of the study and without prior written approval fro m Dermavant Sciences , Inc. , Investigators 
in this study may communicate, orally present, or publish in scientific journals or other scholarly media only 
after the following conditions have been met:  
• The results of the study in their entirety have been publicly disclosed by [CONTACT_222223] , Inc. , in an abstract, manuscript, or presentation form; OR  
• The study has been completed at all study sites for at least 5  years.  
No such communication, presentation, or publication will inclu de Dermavant Sciences , Inc.  confidential 
information (see Section  11.1.4 ). 
The Investigator will submit any proposed publication or presentation alo ng with the respective scientific 
journal or presentation forum at least [ADDRESS_341763] to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold publication or 
presentation for an additional 60  days in order to obtain patent protection if deemed necessary.  
11.2.3  Posting of Information on Publicly Available Clinical Trial R egisters   
Study information from this protocol will be posted on publicly available clinical trial registers as required by 
[CONTACT_5279].  Results will be posted as requ ired. 
11.3 Joint Investigator/Sponsor Responsibilities   
11.3.[ADDRESS_341764] access to the 
Investigator’s source documentation in order to verify the data recorded in the CRFs for consistency.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341765] of any 
inspection or audit . 
11.3.3  Study Discontinuation   
The Sponsor reserves the right to terminate the study at any time.  Should this be necessary, the Sponsor will 
arrange discontinuation procedures and noti fy the appropriate regulatory authority(ies), IRBs, and IECs.  In 
terminating the study, the Sponsor and the Investigator will assure that adequate consideration is given to the 
protection of the subjects’  interests.  
 
 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 65 12 References   
Bashaw ED, et al. Maximal usage trial: an overview of the design of systemic bioavailability trial for topi[INVESTIGATOR_279994]. Ther Innovation & Regulatory Science. 2014;1 -8 
Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483 -94. 
Cappon GD and Hurtt ME.  Developmental toxicity of the kidney.  In:  Kapp RW and Yyl L, editors.  
Reproductive Toxicology, Target Organ Series, 3rd edition.  [LOCATION_001]:Informa Healthcare , 2010:193 -204. 
Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manual JC. The burden of atopic dermatitis: impact 
on the patient, family, and society. Pediatr Dermatol. 2005; 22: 192 -9. 
Frazier KS and Seely JC.  Urinary system.  In:  Sahota PS, Po pp JA, Hardisty JF and Gopi[INVESTIGATOR_92063] C, editors.  
Toxicologic Pathology:  Nonclinical Safety Assessment.  CRC Press, 2013:421 -84. 
Furue, M, Hashimoto -Hachiya, Tsuji, G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J 
Mol Sci. 2019; 20(21), 5 424. 
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato -Venereologica Supplementum. 
1980;92:44 -7. 
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity (EASI) 
index: assessment of reliability  in atopic dermatitis. Experimental Dermatol. 2001: 10:[ADDRESS_341766] Dermatol.  1998; 111:320 -6. 
Lewis -Jones S. quality of life and childhood atopic dermat itis: the misery of living with childhood eczema, In 
J Clin Pract. 2006; 60:[ADDRESS_341767] Dermatol.  2008; 128:1728 -36. 
Peppers J, Paller AS, Maeda -Chubachi T, Wu S, Robbins K, Gallagher J, Kraus JE. A phase 2 randomized 
dose-finding study of tapi[INVESTIGATOR_191752] ([COMPANY_004]2894512 cream) for the treatment of atopic dermatitis. J Am Acad 
Dermatol. 2019; 8 0:89-98. 
Smith, SH, Jayawickreme, C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, 
Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, 
Moore JT, Cote -Sierra J . Tapi[INVESTIGATOR_279995] a natural AhR agonist that resolves skin inflammation in mice and 
humans. J Investigative Dermatol. 2017; 137(10), 2110 –2119.  
Zoetis T and Hurtt ME.  Species comparison of anatomical and functional renal development.  Birth Defects 
Research Part B.  2003;68: 111-120. 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 66 13 Appendices   
Appendix 1: Criteria for Atopic Dermatitis Diagnosis   
Major Criteria (must have at least three)  
• Pruritus  
• Typi[INVESTIGATOR_22784]:  
• Adults: flexural lichenification or linearity  
• Children and infants: involvement of facial and extensor surfaces  
• Chronic or chronically relapsing dermatitis  
• Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)  
Minor Criteria (must have at least three)  
• Xerosis  
• Ichthyosis/keratosis pi[INVESTIGATOR_22785]/palmar hyperlinearity  
• Immediate (Type 1) skin test reactivity  
• Elevated serum IgE  
• Early age at onset  
• Tendency to skin infections (Staphylococcus aureus, herpes simplex)/impaired cellular immunity  
• Tendency to nonspecific hand/foot dermatitis  
• Nipple eczema  
• Cheilitis  
• Recurrent conjunctivitis  
• Dennie -Morgan infraorbital fold  
• Keratoconus  
• Anterior subcapsular cataracts  
• Orbital darkening  
• Facial pallor/erythema  
• Pi[INVESTIGATOR_80166]  
• Anterior neck folds  
• Itch when sweating  
• Intolerance to wool and lipid solvents  
• Perifollicular accentuation  
• Food intolerance  
• Course influenced by [CONTACT_222224]/emotional factors  
• White dermographism/delayed blanch  
 
From Hanifin , 1980.   
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 67 Appendix 2: Fitzpatrick Skin Type Scale   
 
Skin Type  Sunburn Tendency  Suntan Tendency  
Type I  Always burns easily  Never tan  
Type II  Always burns easily  Tans slightly  
Type III  Burns moderately  Tans gradually  
Type IV  Burns minimally  Tans moderately  
Type V  Rarely burns  Tans profusely  
Type VI  Never burns  Tans profusely  
 
  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 68 Appendix 3: Validated Investigator Global Assessment scale for Atopic Dermatitis   
Instructions:  
The vIGA AD™  score is selected using the descriptors below that best describe the overall appearance of the 
lesions at a given time point. It is not necessary that all characteristics under Morphological Description be 
present.  
 
 
Score  Morphological Description  
0 – Clear No inflammatory signs of atopic dermatitis (no erythema, no 
induration/papulation, no lichenification, no oozing/crusting). Post -inflammatory 
hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_22765].  
1 – Almost clear  Barely perceptible erythema, barely perceptible induration/papulation, and/or 
minimal lichenification. No oozing or crusting.  
2 – Mild  Slight but definite erythema (pi[INVESTIGATOR_8745]), slight but definite induration/papulation, and/or 
slight but definite lichenification. No oozing or crusting.  
3 – Moderate  Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, 
and/or clearly perceptible lichenification. Oozing and crusting may be present.  
4 – Severe  Marked erythema (deep or bright red), marked induration/papulation, and/or 
marked lichenification. Disease is widespread in extent. Oozing or crusting may be 
present.  
Notes:  
1. In indeterminate cases, please use extent to differentiate between scores.  
For example:  
Patient with marked erythema (deep or bright red), marked pap ulation and/or marked lichenification that is 
limited in extent, will be considered “3 – Moderate” . 
2. Excoriations should not be considered when assessing disease severity.  
 
Copyright ©2017 Eli Lilly and Company – Used with the permission of Eli Lilly and Company under a Creative Commons  
Attribution -No Derivatives 4.0 International License – https://creativecommons.org/licesnses/by -nd/4.0/  
  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 70 Calculation of EASI score (scalp excluded)  
Four anatomic sites – head, upper extremities, trunk, and lower extremities – are assessed for erythema, 
edema/pa pulation,  excoriation and lichenification as seen on the day of the examination.  The severity of each 
sign is assessed using a 4 -point scale , half points may be used (e.g. 0.5, 1.5, 2.5) : 
0 = None ( Absent ) 
1 = Mild  
2 = Moderate  
3 = Severe  
The area affected by [CONTACT_222225] a given anatomic site is estimated as a percentage of the total area of that 
anatomic site, based on the %BSA calculation, and assigned a numerical value according to the degree of AD 
involvement .  For the purpose of assigning a numerical value for each anatomic site, %BSA ranges will be 
used as follows:  
0 = no (0%) involvement  
1 = > 0% to < 9.50% involvement   
2 = ≥ 9.50% to < 29. 50% involvement   
3 = ≥ 29.50% to < 49.50% involvement   
4 = ≥ 49.50% to < 69.50% involvement   
5 = ≥ 69.50% to < 89.50% involvement   
6 = ≥ 89.50% to 100% involvement   
The EASI score will be calculated in the CRF based on the subject’s age, the rating scores for each region, 
and the number of handprints involved for each region.   
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 73 Appendix 5: Local Tolerabi lity Scale  Assessment   
At each specified study visit, the Investigator (or qualified evaluator) will assess the presence and overall 
degree of irritation at the application sites,  according to the 5 -point scale below.  The score will ideally 
represent an “average” across all application sites.  To the fullest extent possible, the same Investigator (or 
designated evaluator) will perform all tolerability assessments for an individual  subject throughout the study.   
If the subject  is applying study treatment to “sensitive areas” ( e.g., genitals, face, neck, and skin folds), then 
also assess the degree of irritation for these areas.  
Local Tolerability Scale – Dryness, Erythema, and Peeling  
Score  Severity  Description  
0 No irritation  No evidence of local irritation/intolerance  
1 Mild  Minimal erythema and/or edema, slight glazed appearance  
2 Moderate  Definite erythema and/or edema with peeling and/or cracking but does not 
require treatment modification  
3 Severe  Erythema, edema glazing with fissures, few vesicles or papules  
4 Very Severe  Strong reaction spreading beyond the treated area, bullous reaction, 
erosions  
 
  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 74 Appendix 6: The Protocol Amendment Summary of Changes Tabl e  
Protocol Section  Description of Change  Rationale  
Medical Monitor/Sponsor Information 
Page  Sponsor contact [CONTACT_280020].  
Secondary MM was add ed. Sponsor contact [CONTACT_280021], therefore it will be 
provided separately. Secondary MM was 
inadvertently not included in the original 
protocol.  
Synopsis  
Section 4.[ADDRESS_341768] assessment of 
AD. 
Synopsis  
Section 2 Objectives and Endpoints  
Section 10.4.4  Efficacy Analyses  The secondary endpoint: “BSA x vIGA -
AD™ values and change from Baseline 
at each study visit”  
 
Was changed to  
 
“Mean change and percent change in 
BSA x vIGA -AD™ values from 
Baseline at each study visit”  
 To accurately reflect what will be 
analyzed.  
Schedule of Assessments  
Section 5.1.1  Description, Packaging, 
and Labeling  References to “Double Blind Vehicle 
Controlled” and “Vehicle Cream 
removed.  Inadvertently included in the original 
protocol.  
Background  Background information was updated to 
describe development and marketing of 
the molecule, known as tapi[INVESTIGATOR_279996], globally.  Updated information included.  
Section [IP_ADDRESS]  Reproductive and 
Developmental Toxicity  “highly effective method of 
contraception” was changed to 
“acceptable method of contraception”  To align with inclusion/exclusion criteria  
Section [IP_ADDRESS] Repr oductive and 
Developmental Toxicity  
Section 6.3.2  Brief Physical 
Examination  
Section 6.3.4  Clinical Safety 
Laboratory Assessments  Throughout the protocol text was  
updated and/or added to address that 
CBP of adolescents, as well as adults, 
may change during the study warranting 
changes in contraception requirements 
and pregnancy testing.  To ensure safety in all WOCBP.  
Section [IP_ADDRESS]  Body Surface Area 
Affected  
Appendix 4  Details on the calculation of approximate 
% BSA were updated throughout the 
protocol.  The updated text accurately reflects how 
BSA affected will be calculated.  
Section 6.2.2  Eczema Area and 
Severity Index  
Appendix 4  Language in the PP -NRS was updated to 
align verbatim with the copyrighted tool.  
Copyright information below PP -NRS.  Copyrighted version will be used during 
the study.  
Copyright information was inadvertently 
omitted in original protocol.  
Tapi[INVESTIGATOR_222143].: DMVT -505-2104  
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_341769]  Description for reporting folliculitis 
(AESI ) was updated to reflect how data 
will be collected.  
“…associated symptoms (itching, 
burning, pain)…” was changed to 
“…associated signs and symptoms 
(itching, burning, pain, erythema)…”  
Language was changed from ‘indicate 
whether pustular’ to ‘describe 
morphology [scale (keratotic/cornified) 
or no scale (non -keratotic/non -
cornified)].  
‘Infectious/Non -infectious’ was removed 
from possible descriptors.  The updated text aligns with how data 
will be collected in the CRF and reflects 
evolving understanding of t his AESI.  
Appendix 4  Instructions for %BSA calculation were 
updated to accurately reflect how %BSA 
will be calculated.  Description in the original protocol did 
not accurately represent how calculations 
will be done.  
Appendix 4 
 Copyright information was added below 
EASI calculation tables.  Copyright information was inadvertently 
omitted in original protocol.  
Throughout the protocol  Edits were made to remove reference to 
randomization.  
Minor grammatical/formatting updates 
were  made  Clarification  
 